1 2

# Mitochondrial MICOS complex genes, implicated in hypoplastic left heart syndrome, maintain cardiac contractility and actomyosin integrity

- 3 Authors: Katja Birker<sup>1,#</sup>, Natalie J. Kirkland<sup>2,#</sup>, Jeanne L. Theis<sup>3,#</sup>, Zachary C. Fogarty<sup>4</sup>,
- 4 Maria Azzurra Missinato<sup>1</sup>, Sreehari Kalvakuri<sup>1</sup>, Paul Grossfeld<sup>5</sup>, Adam J. Engler<sup>2</sup>, Karen
- 5 Ocorr<sup>1</sup>, Timothy J. Nelson<sup>6</sup>, Alexandre R. Colas<sup>1</sup>, Timothy M. Olson<sup>7</sup>, Georg Vogler<sup>1,\*</sup>,
- 6 and Rolf Bodmer<sup>1,\*</sup>

# 7 Affiliations:

- 8 <sup>1</sup> Development, Aging and Regeneration Program, Center for Genetic Disorders & Aging
- 9 Research, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
- 10 <sup>2</sup> Department of Bioengineering, Sanford Consortium for Regenerative Medicine,
- 11 UCSD, School of Medicine, La Jolla, CA, USA
- <sup>3</sup> Cardiovascular Genetics Research Laboratory, Mayo Clinic, Rochester, MN, USA
- <sup>4</sup> Division of Computational Biology, Department of Quantitative Health Sciences, Mayo
- 14 Clinic, Rochester, MN, USA
- <sup>5</sup> Department of Pediatrics, UCSD School of Medicine, La Jolla, Rady's Hospital MC
- 16 5004, San Diego, CA, USA
- <sup>6</sup> Center for Regenerative Medicine, Division of Pediatric Cardiology, Department of
- 18 Pediatric and Adolescent Medicine, Division of General Internal Medicine, Department
- 19 of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic,
- 20 Rochester, MN, USA.
- <sup>7</sup> Department of Cardiovascular Medicine, Division of Pediatric Cardiology, Department
- 22 of Pediatric & Adolescent Medicine, Cardiovascular Genetics Research Laboratory,
- 23 Mayo Clinic, Rochester, MN, USA.

# 24 **# Co-First authors**

- 25 \* Co-corresponding author: Dr. Rolf Bodmer and Dr. Georg Vogler, Development,
- Aging and Regeneration Program, Center for Genetic Disorders and Aging Research,
- 27 Sanford Burnham Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd., La
- Jolla, CA 92037, USA; Emails: rolf@sbpdiscovery.org; gvogler@sbpdiscovery.org
- 29
- 30 Key words: Congenital heart disease, Drosophila, CHCHD3, CHCHD6, SAM50,
- 31 *ATPsynthase*, HLHS, human iPSC, cardiomyocytes
- 32

## 33 ABSTRACT

34 Hypoplastic left heart syndrome (HLHS) is a severe congenital heart disease (CHD) with 35 a likely oligogenic etiology, but our understanding of the genetic complexities and 36 pathogenic mechanisms leading to HLHS is limited. We therefore performed whole 37 genome sequencing (WGS) on a large cohort of HLHS patients and their families to 38 identify candidate genes that were then tested in Drosophila heart model for functional 39 and structural requirements. Bioinformatic analysis of WGS data from an index family 40 comprised of a HLHS proband born to consanguineous parents and postulated to have a 41 homozygous recessive disease etiology, prioritized 9 candidate genes with rare, predicted damaging homozygous variants. Of the candidate HLHS gene homologs 42 43 tested, cardiac-specific knockdown (KD) of mitochondrial MICOS complex subunit 44 dCHCHD3/6 resulted in drastically compromised heart contractility, diminished levels of 45 sarcomeric actin and myosin, reduced cardiac ATP levels, and mitochondrial fission-46 fusion defects. Interestingly, these heart defects were similar to those inflicted by cardiac 47 KD of ATP synthase subunits of the electron transport chain (ETC), consistent with the 48 MICOS complex's role in maintaining cristae morphology and ETC complex assembly. 49 Analysis of 183 genomes of HLHS patient-parent trios revealed five additional HLHS 50 probands with rare, predicted damaging variants in CHCHD3 or CHCHD6. Hypothesizing 51 an oligogenic basis for HLHS, we tested 60 additional prioritized candidate genes in these 52 cases for genetic interactions with CHCHD3/6 in sensitized fly hearts. Moderate KD of 53 CHCHD3/6 in combination with Cdk12 (activator of RNA polymerase II), RNF149 (E3 54 ubiquitin ligase), or SPTBN1 (scaffolding protein) caused synergistic heart defects, 55 suggesting the potential involvement of a diverse set of pathways in HLHS. Further 56 elucidation of novel candidate genes and genetic interactions of potentially disease-57 contributing pathways is expected to lead to a better understanding of HLHS and other 58 CHDs.

### 59 **INTRODUCTION**

60 Hypoplastic left heart syndrome (HLHS) is a birth defect that accounts for 2-4% of 61 congenital heart defects (CHDs), equal to 1000-2000 HLHS births in the United States 62 per year. HLHS has been proposed to be caused by genetic, epigenetic, or environmental 63 factors (Crucean et al., 2017; Liu et al., 2017; Yagi et al., 2018; Grossfeld et al., 2019). 64 The severe cardiac characteristics of HLHS include aortic and mitral stenosis or atresia, 65 and reduced size of the left ventricle and aorta; however, there is a spectrum of cardiac 66 phenotypes that can underly HLHS pathophysiology (Theis, Hrstka, et al., 2015; Crucean 67 et al., 2017; Mussa and Barron, 2017; Grossfeld et al., 2019). If not treated with 68 reconstructive heart surgeries or cardiac transplantation, infants born with HLHS will not 69 survive (Grossfeld et al., 2019). To date, the standard treatment for this disease is a three-70 stage surgical procedure, which begins neonatally and aims overall to achieve right 71 ventricle-dependent systemic circulation and deliver oxygen-poor blood more directly to 72 the lungs (Mussa and Barron, 2017). Although the surgical procedures correctly divert left 73 ventricular function to the right ventricle, there is a subgroup of HLHS patients who are at 74 risk of latent heart failure, which is often preceded by reduced ejection fraction (Altmann 75 et al., 2000; Mcbride et al., 2008; Theis, Zimmermann, et al., 2015).

76 Although several studies have examined the molecular underpinnings of HLHS, 77 the number of genes associated with this disease is small (e.g. NKX2-5, NOTCH1, ETS1, 78 MYH6, LRP2 and CELSR1), and they are not vet conclusively determined as causal for 79 HLHS (Garg et al., 2005; Ye et al., 2009; Kobayashi et al., 2014; Theis, Hrstka, et al., 80 2015; Tomita-mitchell et al., 2016; Theis et al., 2020, 2021, 2022). Defining pathogenic 81 mechanisms has proved elusive given the oligogenic complexity of HLHS. Overall, there 82 is a great need to functionally evaluate newly emerging HLHS candidate genes to 83 understand how they may contribute to the molecular, cellular, and morphological 84 processes underlying HLHS.

*Drosophila* is well-suited for modeling genetic underpinnings of CHDs: many of the genes and gene programs found in the *Drosophila* heart are evolutionarily conserved, including a core set of cardiogenic transcription factors and inductive factors (e.g. *Nkx2*-

*5/tinman*) (Bodmer, 1995; Cripps and Olson, 2002; Bier and Bodmer, 2004; Bodmer and
Frasch, 2010; Ahmad, 2017), approximately 75% of known human disease-causing
genes having fly orthologs (Bodmer and Frasch, 2010; Pandey and Nichols, 2011; Ugur,
Chen and Bellen, 2016), and the developing mammalian and *Drosophila* hearts share
developmental similarities, such as their origin within the mesoderm.

93 Mitochondria have been postulated to play a critical role in HLHS pathogenesis. 94 For example, a recent study reported that cardiomyocytes derived from iPSCs of HLHS 95 patients (iPSC-CM), who later developed right ventricular failure, had reduced 96 mitochondrial concentration, ATP production, and contractile force (Paige et al., 2020). 97 This study revealed downregulated expression of genes involved in mitochondrial 98 processes, such as ATP synthesis coupled electron transport. Another study of HLHS 99 patient-derived iPSC-CMs revealed reduced mitochondrial size, number, and malformed 100 mitochondrial inner membranes using transmission electron microscopy (Yang et al., 101 2017). Similarly, an HLHS mouse model with Sap130 and Pcdha9 mutations showed 102 mitochondrial defects manifested as reduced cristae density and smaller mitochondrial 103 size (Liu et al., 2017). Despite a lack of understanding of the exact mitochondrial 104 mechanisms underlying HLHS pathogenesis, recent experimental and bioinformatic data 105 suggest an underlying role of mitochondria in HLHS.

106 Here, a cohort of 183 HLHS proband-parent trios underwent whole genome 107 sequencing (WGS) to identify candidate genes, including a prioritized consanguineous 108 family where genes harboring rare, predicted damaging homozygous variants were 109 investigated (Theis and Olson, 2022). Among the resulting candidate HLHS genes tested 110 in Drosophila, cardiac-specific knockdown (KD) of CHCHD3/6 (coiled-coil-helix-coiled-111 coil-helix-domain-containing protein 6) of the MICOS (mitochondrial contact site and 112 cristae organization system) complex exhibited severe heart structure and function 113 defects. The MICOS complex is an eight-subunit complex in mammals (five in Drosophila) 114 located in the inner mitochondrial membrane that is necessary to maintain cristae 115 morphology and ATP production. It is closely associated and interacts with SAM50 116 (sorting and assembly machinery), which is located in the outer mitochondrial membrane 117 (Ott et al., 2012; Kozjak-Pavlovic, 2017). The MICOS complex's role in cardiac

118 development and functional homeostasis is not known but is likely important for efficient 119 ATP production. We observed reduced contractility upon cardiac-specific dCHCHD3/6 120 KD, diminished sarcomeric Actin and Myosin levels, as well as severe mitochondrial 121 morphology defects, which manifested as fragmented and aggregated structures. Similar 122 phenotypes were observed upon cardiac KD of other MICOS complex genes, as well as 123 other mitochondrial genes such as ATP synthase (complex V), specifically ATP synthase 124 B and  $\beta$ . We also found significantly diminished proliferation of human induced pluripotent 125 stem cell (iPSC)-derived ventricular-like cardiomyocytes (VCMs) upon KD of MICOS 126 genes. Finally, a family-based candidate gene interaction screen in Drosophila revealed 127 three genes that genetically interact with dCHCHD3/6: Cdk12 (activator RNA polymerase 128 II activator), RNF149 (E3 ubiquitin ligase), SPTBN1 (scaffolding protein). In summary, 129 CHCHD3/6 and other components important for mitochondrial homeostasis were 130 identified as critical for establishing and maintaining cardiac structure and function, and 131 likely contribute to HLHS and/or latent heart failure following surgical palliation.

# 132 **RESULTS**

# 133 Family Phenotype

134 Family 11H is of white ancestry and comprised of a male with HLHS, his parents, 135 and two siblings, they were all phenotypically characterized by echocardiography and 136 underwent WGS. A homozygous recessive disease mode of inheritance was postulated 137 due to reported consanguinity between the mother and father and absence of structural 138 and myopathic heart disease in the parents. The siblings also had normal 139 echocardiograms (Figure 1A). The 11H proband had latent decline of right ventricular 140 ejection fraction several years after surgical palliation. In addition to HLHS, he was 141 diagnosed with developmental delay, cerebral and cerebellar atrophy, white matter loss, 142 decreased muscle mass, and a body mass index <1%, traits that have previously been 143 related to mitochondrial dysfunction (Romanello and Sandri, 2016; Alston et al., 2017).

#### 144 Whole Genome Sequencing and Bioinformatics Analysis of 11H family

145 Array comparative genomic hybridization ruled out a chromosomal deletion or 146 duplication in the proband. WGS was carried out on genomic DNA samples from the five 147 family members, based on paired-end reads that passed quality control standards; 99.4% 148 of the reads mapped to the genome. After marking and filtering out duplicate reads, over 149 91% of the hq38 human reference genome had coverage. The average depth across the 150 genome was 63X and an average of 89% of the genome demonstrated a minimal read 151 depth of 20 reads. Filtering for rare variants that were homozygous in the HLHS proband 152 revealed nine candidate genes. Three genes had a missense variant (SZT2, MTRR, 153 *MBTPS1*) whereas the remaining six genes were found to have a non-coding variant 154 within the promoter (CAP1, DGKE), 5' untranslated region (RHBDL2, RNF149, 155 C17orf67), or intron (CHCHD6) (Supplementary Table 1) (Marian and Belmont, 2011). 156 While six of the variants were also found to be homozygous in an unaffected sibling, the 157 associated candidate genes were not excluded from downstream analyses based on the 158 postulated oligogenic nature of HLHS, and incomplete penetrance of individual variants, 159 as observed in a digenic mouse model (Yagi et al., 2018).

### 160 Candidate HLHS gene knockdown in *Drosophila* reveals requirement for

#### 161 CHCHD3/6 in establishing cardiac structure and function

162 To test whether the HLHS candidates had significant requirements in the heart, we 163 utilized the established Drosophila heart model and cardiac-specific RNAi KD. First, the 164 nine candidate genes were assigned their respective Drosophila homologs; seven out of 165 nine of the human HLHS candidate genes had *Drosophila* orthologs (Figure 1B) (Hu et 166 al., 2011). The Drosophila Gal4-UAS system (Brand and Perrimon, 1993) was used to 167 test candidate genes for their role in heart function using temporal and/or spatial KD via 168 RNAi. The Hand<sup>4.2</sup>-Gal4 driver was used for initial screening because it is a strong post-169 mitotic and heart-specific driver, which is expressed throughout life in the cardiomyocytes 170 (CMs) and pericardial cells (PCs) (Han and Olson, 2005; Han et al., 2006) (Figure 1C). 171 3-week-old (mid-adult stage) female flies were used to test the seven candidate genes. 172 Hand<sup>4.2</sup>-Gal4 KD of capt (actin binding protein, negatively regulating actin filament 173 assembly), Dgkepsilon (Diacyl glycerol kinase, DGKE), and CHCHD3/6 (Mitochondrial 174 inner membrane protein of the MICOS complex, required for fusion) produced defects in

175 the fly hearts, such as reduced cardiac output, reduced fractional shortening, and 176 arrhythmicity (Figure 1B). Of those, CHCHD3/6 KD gave the most severe cardiac defects 177 with strongly reduced fractional shortening, a measure of cardiac contractility. Systolic 178 rather than end-diastolic diameter was increased, which suggests systolic dysfunction 179 (Supp. Figure 1A-C). Since reduced contractility was previously shown in animals with 180 reduced mitochondrial gene expression, we hypothesized CHCHD3/6 KD may reduce 181 contractility via a role in mitochondrial function (Bhandari, Song and Dorn, 2015; 182 Martínez-Morentin et al., 2015; Tocchi et al., 2015).

183 To test how early the cardiac phenotype of CHCHD3/6 KD manifests in adult 184 stages, 1-week old Hand<sup>4.2</sup>-Gal4 KD of CHCHD3/6 flies were examined, using several 185 independent RNAi lines for CHCHD3/6. These flies also had reduced fractional 186 shortening, i.e., reduced contractility due to systolic dysfunction (Figure 1D-F). This phenotype was observed in cardiac assays of intact flies (see Methods) (Supp. Figure 187 188 **1D-F**), as well as in the semi-intact adult heart preparation that lacks neuronal inputs 189 (SOHA; (M Fink et al., 2009)). To further validate a cardiac-specific role for CHCHD3/6, 190 as opposed to non-autonomous effects from other tissues, we performed KD of 191 CHCHD3/6 using Dot-Gal4 (expressed in pericardial cells, PC, which also express Hand), 192 Mef2 (Myocyte enhancer factor 2)-Gal4 (a pan-muscle driver), or elav-Gal4 (a pan-193 neuronal driver) (see Methods). A large reduction in fractional shortening was only 194 observed with the pan-muscle driver that includes cardiac muscle, but not with the PC or 195 neuronal drivers, confirming a cardiomyocyte-autonomous effect (Supp. Figure 1J-L). Both CHCHD3/6<sup>RNAiA</sup> and CHCHD3/6<sup>RNAiB</sup> lines had the same predicted off-target gene, 196 197 Duox but Hand<sup>4.2</sup>-Gal4 driven KD of Duox had no effect on fractional shortening. 198 confirming that the cardiac effects were due to CHCHD3/6 KD (Supp. Figure 1M).

# 199 Temporal requirements for CHCHD3/6 in maintaining heart function

We next sought to understand if *CHCHD3/6* has different temporal requirements for its effects on heart structure and function, since hearts of operated HLHS patients often develop reduced ejection fraction and heart failure, including the 11H proband. First, to assess whether *CHCHD3/6* could have a role in early heart development, we mined

204 embryonic heart-specific single-cell transcriptomic data (Vogler et al., 2021) and found 205 that CHCHD3/6 was expressed in Drosophila cardioblasts (CBs), along with other 206 cardiogenic factors (*tinman*, H15, and Hand) (Figure 2A). Next, we analyzed CHCHD3/6 207 mutant embryos for cardiac phenotypes. Late-stage 16-17 CHCHD<sup>D1</sup> / CHCHD<sup>DefA</sup> trans-208 heterozygous embryos were stained for Mef2 (early mesoderm/muscle-specific 209 transcription factor) and Slit (secreted protein in the heart lumen) but did not exhibit overt 210 cardiac specification defects (Figure 2B). We used the *tinD*-Gal4 driver (*tinman enhancer*) 211 D (Yin, Xu and Frasch, 1997; Xu et al., 1998) to test whether CHCHD3/6 KD in the dorsal 212 mesoderm (including cardiac mesoderm) during embryonic stages 10-12 affects 213 establishment of adult heart function. We reared tinD-Gal4>CHCHD3/6<sup>RNAiA</sup> flies at 29°C 214 throughout life to achieve high KD efficiency but did not observe reduced fractional 215 shortening or any other functional defects, relative to controls (Figure 2C, D). Thus, KD 216 of CHCHD3/6 in the embryonic cardiac mesoderm is not sufficient to impact later heart 217 function.

218 To further investigate the temporal requirement of CHCHD3/6 during heart 219 development, we made use of the temperature-dependence of Gal4-mediated KDs (less 220 KD efficiency at 19°C, greater KD efficiency at 29°C; see Figure 2E for experimental 221 strategy). *Hand<sup>4.2</sup>-Gal4* mediated KD of *CHCHD3/6*<sup>RNAiA</sup> had strong contractility defects already at 19°C (Figure 2F). A weaker RNAi KD line CHCHD3/6<sup>RNAiC1</sup> (see Figure 1D-222 223 F) caused no reduction in fractional shortening at 19°C (Figure 2F), whereas at 29°C 224 fractional shortening was reduced similarly to the stronger KD line 19°C. To examine 225 different developmental windows, Hand<sup>4.2</sup>-Gal4>CHCHD3/6<sup>RNAiC1</sup> flies were shifted from 226 19°C to 29°C at either early pupal stages or early adult stages (after eclosion) until 1 week 227 of age when heart function was assessed (Figure 2E). Interestingly, both treatments 228 caused a substantial reduction in fractional shortening, although somewhat less than at 229 29°C throughout life (Figure 2G-I). This suggests that CHCHD3/6 is not only required 230 during pupal development, but also at adult stages for maintaining robust heart function.

# Cardiac knockdown of *Drosophila CHCHD3/6* results in severe reduction of sarcomeric Actin and Myosin levels

233 The strong heart functional defects upon CHCHD3/6 KD suggest that the 234 contractile machinery in cardiomyocytes is severely compromised. To probe for 235 contractile abnormalities, we examined several sarcomeric components, including 236 filamentous (F-) Actin, Myosin heavy chain, Obscurin (present at the M-line),  $\alpha$ -Actinin 237 (present at the Z-line), and Sallimus (Titin component in flies, localized near the Z-line) 238 (Figure 3A). The intensity of F-actin staining with phalloidin was severely diminished in 239 the working myocardium of Hand<sup>4.2</sup>-Gal4>CHCHD3/6 KD flies (Figure 3B-D, arrows in 240 **B**). Because Hand<sup>4.2</sup>-Gal4 expression is less in ostial cardiomyocytes (inflow valves), F-241 actin staining in ostial sarcomeres was minimally affected, if at all (Figures 3B, 242 arrowheads). Like F-actin staining, Myosin staining was also dramatically diminished 243 (Figure 3E,I) In contrast, Obscurin and α-Actinin staining was only moderately reduced 244 (Figure 3F,G,J,K), and Sallimus staining was unaffected (Figure 3H, L). These findings 245 suggest that loss of CHCHD3/6 function did not abrogate the overall sarcomeric 246 organization, but instead differentially affected the abundance of individual sarcomeric 247 proteins. Overall, the strongly diminished F-actin and Myosin levels in cardiac myofibrils 248 is likely responsible for the diminished contractile capacity of the ATP-dependent 249 actomyosin network in CHCHD3/6 KD hearts.

# Actin polymerization components do not mediate sarcomeric actomyosin reduction upon cardiac CHCHD3/6 knockdown

252 Due to the strong reduction of F-actin levels observed with reduced CHCHD3/6 253 expression, we hypothesized that globular (G) to F-actin polymerization was disrupted. If 254 CHCHD3/6 KD compromises mitochondrial ATP production in high energy-demanding 255 CMs, the reduced ATP levels could disrupt actin polymerization and lead to reductions in 256 F-actin and other sarcomeric proteins (Carlier, Pantaloni and Korn, 1984; Korn, Carlier 257 and Pantaloni, 1987; Carlier, 1998). To test this, we reduced the cardiac expression of 258 several actin polymerizing and depolymerizing genes (Supp. Figure 2A). Cardiac KD of 259 Arp2/3, gel, Chd64, WASp, and TM1 caused slightly reduced fractional shortening, but 260 not as severe as with CHCHD3/6 KD (Supp. Figure 2A, B). Moreover, cardiac KD of Arp, 261 Chd64, or WASp resulted in substantial myofibrillar disorganization, including gaps, but 262 did not appear to produce the CHCHD3/6 KD-like reduction in sarcomeric F-actin levels

(WASp example shown in Supp. Figure 2C). Overall, KD of any of these genes involved
in F-actin polymerization could not recapitulate the reduced myocardial F-actin intensity
with normal sarcomeric patterning seen with *CHCHD3/6* KD. Therefore, it appears
unlikely that defects in actin polymerization mediate the effects of *CHCHD3/6* KD.

### 267 CHCHD3/6 knockdown in flight or heart muscles results in defective mitochondria

268 Next, we hypothesized that the reduced contractile capacity and altered F-actin and 269 Myosin in CHCHD3/6 KD hearts was due to reduced mitochondrial function. We first 270 examined mitochondrial integrity and sarcomeric actin staining in indirect flight muscles 271 (IFMs), since their mitochondria are easily visualized due to their large size. Upon 272 CHCHD3/6 KD in IFMs using the pan-muscle driver Mef2-Gal4, we observed reduced F-273 actin staining and diminished sarcomere pattern definition (Figure 4A), similar to the 274 cardiac phenotype (Figure 3B). This further indicated that the CHCHD3/6 KD phenotype 275 is not specific to cardiac tissue, but likely affects all muscles. We then examined 276 mitochondrial integrity upon CHCHD3/6 KD in IFMs expressing Mito::GFP (complex IV), 277 and with antibodies against ATP synthase (complex V). Strikingly, Mito::GFP and ATP 278 synthase staining revealed mitochondrial defects as manifested in aggregates (Figure 4B-279 E), which is suggestive of an imbalance between fusion and fission.

Next, we assayed ATP synthase staining in *Hand*<sup>4.2</sup>-*Gal4*>*CHCHD3*/6<sup>RNAiA</sup> hearts. We again observed mitochondrial aggregates, along with reduced F-actin and ATP synthase staining, relative to controls (**Figure 4F-I**). Furthermore, *Hand*<sup>4.2</sup>-*Gal4*, Mito::GFP>CHCHD3/6<sup>RNAiA</sup> hearts also exhibited mitochondrial aggregates and reduced intensity of Mito::GFP (**Figure 4G-I**). Taken together, these data show that *CHCHD3*/6 KD disrupts cardiac mitochondrial morphology and causes the formation of mitochondrial aggregates.

# 287 Mitochondrial ATP synthase (complex V) KD causes similar contractile dysfunction 288 and diminished sarcomeric F-Actin staining as with CHCHD3/6 KD

289 To determine whether KD of other mitochondrial genes impaired contractility and 290 sarcomeric F-actin accumulation similar to that of *CHCHD3*/6 KD, we screened RNAi

291 lines from different mitochondrial functional groups (FlyBase.org GO term mitochondrion: 292 0005739) using the Hand<sup>4.2</sup>-Gal-4; tdtK driver for high-throughput heart imaging analysis 293 (see Methods; Vogler, 2021). Cardiac KD of 17 of the 21 mitochondrial genes tested 294 displayed reduced fractional shortening, most commonly due to systolic dysfunction 295 (Supplementary Table 2). However, only KD of ATP synthase subunits reduced both 296 fractional shortening and F-actin staining (Figure 4J-M, Supp. Figure 3A). Remarkably, 297 F-actin staining in Hand<sup>4.2</sup>-Gal4, tdtK>ATPsynβ/B<sup>RNAi</sup> hearts resembled that of 298 CHCHD3/6 KD, i.e. weakly stained myocardial myofibrils relative to ostial myofibrils 299 (Figure 4M). These findings suggested that the heart dysfunction observed upon 300 CHCHD3/6 KD may be mediated via defects in ATP synthase.

# 301 ATP production is reduced upon CHCHD3/6 knockdown

302 Disrupted mitochondrial organization and reduced staining of OXPHOS components 303 likely impacts ATP production and could explain cardiac functional and structural defects. 304 We therefore directly measured ATP concentration in 1-week old female hearts with cardiac CHCHD3/6 KD. We observed reduced ATP levels upon CHCHD3/6 KD compared to 305 306 controls, and these ATP levels were similar to those measured in response to cardiac ATP-307  $syn\beta$  KD (**Figure 4N**). This further strengthens the hypothesis that the cardiac functional 308 deficits in contractility induced by CHCHD3/6 KD are due to mitochondrial defects that 309 considerably reduce ATP levels in the heart necessary to build and maintain myofibrils.

#### 310 CHCHD3/6 knockdown in all muscle cells is lethal or reduces climbing ability

311 To further characterize the impact of CHCHD3/6 KD induced mitochondrial defects 312 on muscle function, we assessed locomotive ability. When reared throughout development at 25°C. Mito::GFP: *Mef2*>CHCHD3/6<sup>RNAiA</sup> flies were pupal lethal. However. 313 with a moderate strength RNAi line (Mito::GFP; Mef2>CHCHD3/6<sup>RNAiC1</sup>) flies did eclose, 314 315 but with reduced viability, especially for males (Supp. Figure 3B). Flies are negatively 316 geotactic and will rapidly climb up the sides of a vial when tapped down. In 1-week of 317 age, male and female Mito::GFP; *Mef2>CHCHD3/6*<sup>RNAiC1</sup> flies, this activity was greatly 318 reduced compared to controls (Supp. Figure 3C), supporting the hypothesis that 319 CHCHD3/6 KD reduces muscle function.

# 320 Knockdown of SAM50 and Mitofilin cause cardiac defects, and SAM50 genetically 321 interacts with CHCHD3/6

322 To further explore the role of the MICOS complex to maintain myofibrillar structure, 323 we tested five MICOS complex-associated components for their requirement in cardiac contractility and sarcomeric F-actin levels (Figure 5A). Hand<sup>4.2</sup>-Gal4-mediated KD of 324 325 Mitofilin or Sam50 resulted in a significant reduction in fractional shortening, due to 326 systolic dysfunction, mimicking CHCHD3/6 KD defect in contractility, whereas APOOL, 327 *Mic13* or *Mic10* KD did not exhibit significant effects (Figure 5B, Supp. Figure 4A, B). 328 Of note, none of these five MICOS associated components displayed detectable 329 reduction in sarcomeric F-actin staining upon KD (Supp. Figure 4C).

330 Subsequently, we tested for genetic interactions between CHCHD3/6 and MICOS-331 associated components, since protein-protein interactions among them have been 332 previously described (Ding et al., 2015; Li et al., 2016; Tang et al., 2020). To test for 333 interactions, we generated a Hand<sup>4.2</sup>-Gal4, tdtK; CHCHD<sup>D1/+</sup> heterozygote mutant 334 sensitizer line that had no noticeable cardiac abnormalities (Deng et al., 2016) (Figure 335 5C). Hand<sup>4.2</sup>-Gal4, tdtK; CHCHD<sup>D1/+</sup> crossed to Mitofilin or Sam50 RNAi did not further 336 reduce fractional shortening beyond what was observed in response to KD of the 337 individual genes (Supp. Figure 4D). However, we observed an interaction in the combined Sam50 KD and CHCHD<sup>D1/+</sup> hearts, where F-actin levels were also strikingly 338 339 reduced compared to the single KD, similar the CHCHD3/6 KD (Figure 5D). This 340 suggests that there is a threshold requirement of MICOS/Sam50, which when reached 341 induces reduced contractility AND diminished F-Actin levels.

# 342 Knockdown of MICOS subunits impairs proliferation of human iPSC-derived 343 cardiomyocytes.

We next tested the effects of KD of *CHCHD3/6* and other MICOS-associated components in human cardiomyocytes (CMs) derived from iPSC (hiPSC-CM). Since reduced CM proliferation is hypothesized to be a major contributing factor for the etiology of HLHS (Gaber *et al.*, 2013; Liu *et al.*, 2017; Theis *et al.*, 2020), we focused on proliferation as our readout. We used small interfering RNA (siRNA) (as in (Theis *et al.*,

2020)) to KD genes in hiPSC-CMs. We found that KD of *CHCHD6* and *CHCHD3*, as well
as all other MICOS subunits and *SAM50*, significantly reduced their proliferation in an
EdU incorporation assay (**Supp. Figure 5A, B**), supporting a potential link for *CHCHD6*and other MICOS subunits in HLHS pathogenesis.

# Testing of candidate genes prioritized in HLHS probands with CHCHD3 or CHCHD6 variants reveals novel genetic interactors

Since we found an essential role for *CHCHD3/6* in establishing heart structure and function in the *Drosophila* heart model with possible relevance for HLHS pathology, we assessed the presence of variants in additional HLHS family trios. Among the 183 Mayo Clinic HLHS family trios and pediatric cardiac genomics consortium (PCGC) databank (Jin *et al.*, 2017), there were three probands with variants in *CHCHD6* (including 11H) and four with *CHCHD3* variants (**Supplementary Table 3**).

361 The relative abundance of rare, predicted damaging CHCHD3/6 variants in the 362 Mayo Clinic cohort, together with the postulated oligogenic nature of HLHS, led us to test 363 for genetic interactions between CHCHD3/6 and other HLHS candidate genes. 364 Specifically, we prioritized candidate genes with rare coding and regulatory variants 365 identified in HLHS probands who also carried CHCHD3- or CHCHD6-variants (Supplementary Table 4). We generated a CHCHD3/6 sensitizer line, Hand<sup>4.2</sup>-Gal4, 366 367 *tdtK*; *CHCHD3/6<sup>RNAiC1</sup>*, which at 21°C does not exhibit significant contractility deficits 368 (Figure 6A). We screened 120 RNAi lines representing 60 candidate HLHS genes for 369 genetic interactions and identified three hits that had contractility defects only when coknocked down with CHCHD3/6<sup>RNAiC1</sup> at 21°C (Figure 6B). Cdk12 (human ortholog: 370 371 CDK12) has been shown to activate RNA polymerase II to regulate transcription 372 elongation (Bartkowiak et al., 2010), Goliath (human ortholog: RNF149) encodes an E3 373 ubiquitin ligase that localizes to endosomes (Yamazaki et al., 2013) and  $\beta$ -Spectrin 374 (human ortholog: SPTBN1) is a scaffolding protein that links the actin cytoskeleton to the 375 plasma membrane. KD of Cdk12 in combination with CHCHD3/6 KD also led to greater 376 lethality of elcosed flies at 1 week-of-age compared to individual gene KD (Figure 6C). While interestingly, we found that co-KD of  $\beta$ -Spectrin and CHCHD3/6<sup>RNAiC1</sup> at 21°C was 377

the only combination that also diminished F-actin and Myosin staining, similar to co-CHCHD3/6<sup>RNAiA</sup> KD (**Figure 6D**). In summary, our approach using a sensitized screening strategy to interrogate genetic interactions between patient-specific candidate genes is a powerful tool to identify novel interactions that are potentially involved in the oligogenic ethology of HLHS and other CHDs.

#### 383 **DISCUSSION**

384 HLHS is characterized by a small left heart, including reduced left ventricle size 385 and mitral and/or atrial atresia or stenosis, and aortic hypoplasia, collectively obstructing 386 systemic blood flow (Tchervenkov et al., 2006). As a consequence, newborns cannot 387 sustain systemic blood flow for more than a few days and therefore require treatment 388 soon after birth. There is a need for improved therapies to treat HLHS patients, and this 389 requires a better understanding of the biology behind HLHS pathogenesis. Here, we 390 probed the genetic basis of HLHS using WGS and powerful bioinformatic gene variant 391 prioritization in a large cohort of HLHS proband-parent trios combined with model system 392 validation.

393 The 11H family was prioritized because of consanguinity, implicating a 394 homozygous recessive mode of inheritance that resulted in a short list of nine candidate 395 genes. These candidate genes were probed in *Drosophila* and iPSC-CMs for a potential 396 role in cardiomyocyte development and function, to gain new insights into HLHS and 397 CHDs in general. Among these HLHS gene candidates, we focused on CHCHD3/6, which 398 has not been previously studied in the heart, and which had striking cardiac functional 399 and structural defects in Drosophila. Specifically, the preliminary gene screen 400 demonstrated that CHCHD3/6 cardiac-specific KD caused reduced contractility and 401 decreased sarcomeric F-Actin and Myosin staining.

402 Our data suggest that *CHCHD3/6* is necessary during larval and early adult stages 403 to maintain contractility in the adult heart. This is relevant since patients with HLHS have 404 both structural heart disease and risk for later myocardial failure (Theis, Zimmermann, *et* 405 *al.*, 2015). The prevailing" no flow, no grow" hypothesis for HLHS pathogenesis surmises 406 that reduced blood flow in the fetal heart causes underdevelopment of the left ventricle

407 (Goldberg and Rychik, 2016; Grossfeld et al., 2019). A reduced ability for the heart to 408 contract in utero, due to reduced CHCHD6 activity, could contribute to decreased 409 ventricular blood flow in the embryo, resulting in an abnormally small left ventricle. 410 Moreover, reduced CHCHD6 activity could compromise right ventricular function later in 411 life (Theis, Hrstka, et al., 2015; Theis, Zimmermann, et al., 2015). In fact, the 11H proband 412 exhibited mildly reduced right ventricular ejection fraction several years after successful 413 surgical palliation. Consistent with our model system, CHCHD6 deficiency could result in 414 cumulative impairment of mitochondrial function, leading to contractile dysfunction (Sun, 415 Youle and Finkel, 2016).

416 CHCHD3/6 KD in the fly heart led to mitochondrial aggregates, with reduced ATP 417 synthase (complex V) levels, and consequently impaired ATP production. Mitochondrial 418 aggregates or fragments could be indicative of an imbalance between fission and fusion. 419 It has previously been reported that CHCHD3 KD in HeLa cells resulted in fragmented 420 mitochondria that was due to improper mitochondrial fusion (Darshi et al., 2011). It has 421 also been demonstrated in yeast that individual or combinatorial loss of MICOS complex 422 proteins disrupt cristae morphology (Friedman et al., 2015), thus suggesting a mechanism 423 by which CHCHD3/6 loss could mediate HLHS pathogenesis. Furthermore, we identified 424 a genetic interaction between SAM50 and CHCHD3/6 that leads to a contractile deficit 425 and diminished sarcomeric F-Actin. Recent findings demonstrate that SAM50 directly 426 interacts with Mic19, the mammalian ortholog of CHCHD3, to mediate inner and outer 427 membrane bridging and cristae morphology (Tang et al., 2020).

428 Our data further suggest that ETC Complex V/ ATP synthase is a potential 429 downstream effector of CHCHD3/6 and MICOS complex function. Individual KD of ATP 430 synthase subunits resulted in reduced fractional shortening and reduced sarcomeric 431 actin. As a result, we hypothesize reduced CHCHD3/6 expression affects ETC function, 432 specifically ATP synthase, leading to reduced ATP production. OXPHOS complex 433 assembly has been shown to be disrupted upon MICOS depletion, and we speculate ATP 434 synthase may be disrupted when CHCHD3/6 is reduced (Cogliati, Enriquez and 435 Scorrano, 2016). Consistent with this, we observe depletion of ATP synthase levels upon 436 CHCHD3/6 KD.

437 Finally, we tested a potential oligogenic basis of HLHS in our family-based 438 CHCHD3 and CHCHD6 interaction screen and identified three hits that reduced fractional 439 shortening only in conjunction with CHCHD3/6, but not on their own. Co-KD of Cdk12 and 440 CHCHD3/6 also reduced fractional shortening, and caused greater lethality relative to 441 Cdk12 KD alone. Cdk12 activates RNA polymerase II to regulate transcription elongation 442 (Bartkowiak et al., 2010). We postulate that since CHCHD3/6 is a nuclear-encoded gene, 443 reducing transcription with Cdk12 KD could decrease CHCHD3/6 levels in a background 444 where CHCHD3/6 activity is already compromised. Alternatively, reduced transcription of 445 other nuclear genes associated with ATP production in combination with CHCHD3/6 KD 446 could further reduce ATP levels enough to cause contractility defects. In support of this, 447 a study examining the effects of RMP (RNA polymerase II subunit 5-mediating protein) 448 found that mice with cardiac-specific Rpm KO exhibited reduced fractional shortening and 449 ATP levels, which were attributed to a reduction in mRNA and protein levels of the 450 mitochondrial biogenesis factor PGC1 $\alpha$  (Zhang *et al.*, 2019). The second hit, *Goliath*, is 451 an endosomal ubiguitin E3 ligase. Although Goliath has been implicated in endosomal 452 recycling (Yamazaki et al., 2013), its role in Drosophila mitophagy in vivo has not been 453 examined. Reduced cardiac contractility with co-KD of Gol and CHCD3/6 could result 454 from impaired mitophagy and reduced mitochondrial biogenesis. Together, the 455 accumulation of damaged mitochondria can reduce ATP content required for contraction 456 (Palikaras and Tavernarakis, 2014; Palikaras, Lionaki and Tavernarakis, 2015). The third 457 hit,  $\beta$ -Spectrin, acts as a scaffolding protein. Recent data suggests that the human 458 ortholog, SPTBN1 (Nonerythroid spectrin  $\beta$ ) influences SPTAN1 (Nonerythroid spectrin 459  $\alpha$ ) levels, which has a calmodulin binding domain (Ackermann and Brieger, 2019). 460 Therefore, decreased  $\beta$ -Spec expression could reduce Calmodulin levels, thereby 461 reducing contractility due to the combined reduction in Ca<sup>2+</sup> handling and CHCHD3/6 KD-462 induced reduced ATP levels.

In summary, we have identified a novel mechanism potentially involved HLHS pathogenesis, starting by analyzing WGS data from a prioritized family and large cohort of HLHS patients, followed by functional testing *in vivo* using the *Drosophila* heart model and *in vitro* using human iPSC-derived CMs. Compromised contractile capacity, diminished sarcomeric F-Actin and Myosin accumilation, and mitochondrial dysfunction in *CHCHD3/6* KD *Drosophila* hearts are promising phenotypes that could contribute to
early HLHS manifestations or heart failure complications later in life. Further examination
of the interactions between the MICOS complex and other emerging candidate genes will
identify novel gene functions and pathways that contribute to HLHS pathogenesis.
Furthermore, a detailed elucidation of novel candidate genes and genetic interactions
based on patient-specific rare potentially damaging variants is expected to lead to gene
networks that are relevant for HLHS and other CHDs.

# 475 Acknowledgments

We gratefully acknowledge the patients and families who participated in this study. We thank Marco Tamayo and Bosco Trinh for excellent technical assistance. This work was supported by National Institutes of Health (R01 HL054732 to R.B.). This work was also supported by a grant from the Wanek Foundation at Mayo Clinic in Rochester, M.N., to J.L.T., T.J.N., T.M.O., R.B. and A.R.C.; by the American Heart Association: AHA Predoctoral Fellowship (18PRE33960593 to K.B.) and AHA Postdoctoral Fellowship (20POST35180048 to N.J.K.).

483

# 484 Materials and Methods

#### 485 Study subjects

Written informed consent was obtained for the index family and HLHS cohort,
under a research protocol approved by the Mayo Clinic Institutional Review Board.
Cardiac anatomy was assessed by echocardiography.

### 489 **Comparative genomic hybridization**

To detect an euploidy, array comparative genomic hybridization was performed using a custom 180K oligonucleotide microarray (Agilent, Santa Clara, CA), with a genome-wide functional resolution of approximately 100 kilobases. Deletions larger than 200 kilobases and duplications larger than 500 kilobases were considered clinically relevant.

# 495 Genomic and bioinformatics analysis of 11H family

496 Genomic DNA was isolated from peripheral white blood cells or saliva. WGS and 497 variant call annotation were performed utilizing the Mayo Clinic Medical Genome Facility 498 and Bioinformatics Core. For the family quintet, 101 base pair (bp) or 150 bp paired-end 499 sequencing was carried out on Illumina's HiSeg 2000 or HiSeg 4000 platforms, 500 respectively. Reads were aligned to the hg38 reference genome using BWA version 501 0.7.10 (http://bio-bwa.sourceforge.net/bwa.shtml) and duplicate reads were marked using 502 Picard (http://picard.sourceforge.net). Local realignment of INDELs and base quality 503 score recalibration were then performed using the Genome Analysis Toolkit version 3.4-504 46 (GATK) (McKenna et al., 2010). SNVs and INDELs were called across all samples 505 simultaneously using GATK's Unified Genotype with variant quality score recalibration 506 (VQSR) (Poplin et al., 2018).

507 Variant call format (VCF) files with SNV and INDEL calls from each family member
508 were uploaded and analyzed using Ingenuity Variant Analysis software (QIAGEN,
509 Redwood City, CA) where variants were functionally annotated and filtered by an iterative
510 process. Annotated variants were subject to quality filters and required to pass Variant
511 Quality Score Recalibration (VQSR) and have a genotype quality score ≥20. Variants

512 were excluded if they were located in a simple repeat region identified using tandem 513 repeats finder (Benson, 1999) or were found to have a minor allele frequency >1% in 514 gnomAD v2.1 (Karczewski et al., 2020). Second, functional variants were selected, 515 defined as those that impacted a protein sequence, canonical splice site, microRNA 516 coding sequence/binding site, or transcription factor binding site within a promoter 517 validated by ENCODE chromatin immunoprecipitation experiments (Raney et al., 518 2014). Third, using parental and sibling WGS data, rare, functional variants were then 519 filtered for those that were homozygous recessive in the proband.

## 520 Analysis of HLHS cohort for variants in the MICOS complex

521 WGS was performed on samples from 183 individuals with HLHS and 496 family 522 members by the Mayo Clinic Medical Genome Facility or Discovery Life Sciences. SNVs 523 and INDELs that passed quality control were subject to further filtering based upon rarity 524 (MAF < 0.01) and predicted consequence. Details about the sequencing and subsequent 525 variant filtering to identify HLHS gene candidates have been previously described (Theis 526 et al., 2021). Rare variants from the 183 probands were interrogated for variants in 527 CHCHD3 and CHCHD6 to identify variants that arose de novo or were homozygous 528 recessive, compound heterozygous or X-linked recessive. Next, inherited variants in 529 these genes were analyzed, but stricter thresholds were required to identify the most 530 damaging variants. Missense variants were required to have CADD>24 (corresponds to 531 the upper quartile of the most damaging missense variants) and non-coding variants were 532 required to have a Position Weight Matrix (PWM) score >0.75 from the Factorbook 533 database (selecting for variants predicted to disrupt canonical transcription factor binding 534 sites). In addition to the Mayo Clinic HLHS cohort, the Pediatric Cardiac Genomics 535 Consortium (PCGC) whole exome sequencing dataset was interrogated for candidate 536 genes in the MICOS complex in patients with CHD (Jin et al., 2017).

#### 537 Analysis of CHCHD3 and CHCHD6 variant carriers

538 Using robust bioinformatics algorithms as previously described (Theis and Olson, 539 2022), a broad range of both family-based Mendelian inheritance modeling and cohort-540 wide enrichment analyses were applied to identify additional candidate genes in HLHS

541 probands identified to have a rare, predicted-damaging coding or regulatory variant in 542 *CHCHD3* or *CHCHD6*.

#### 543 *Drosophila* strains and husbandry

544 Drosophila crosses were reared and aged at 25°C, unless otherwise noted. 545 Drosophila orthologs were determined using DIOPT (Drosophila RNAi Screening Center 546 Integrative Ortholog Prediction Tool) which calculates the number of databases that predict orthology (out of a score of 16) (Hu et al., 2011). Fly stocks were obtained from 547 548 Vienna Drosophila Resource Center (VDRC) and Bloomington Drosophila Stock Center 549 (BDSC). Lines include Hand<sup>4.2</sup>-Gal4 (Han et al., 2006), tdtK (Klassen et al., 2017), tinCΔ4-550 Gal4 (Lo and Frasch, 2001), Dot-Gal4 (Kimbrell et al., 2002), Mef2-Gal4 (Ranganayakulu 551 et al., 2010), Mito::GFP (BDSC: 8442), CHCHD<sup>DefA</sup> (BL: 26847), CHCHD3/6 A (VDRC: 552 52251), CHCHD3/6 B (VDRC: 105329), CHCHD3/6 C (BDSC: 51157), CHCHD3/6 D 553 (BDSC: 38984), DUOX (BDSC: 32903), Mitofilin A (VDRC: 47615), Mitofilin B (VDRC: 554 106757), Mic13 A (VDRC: 14283), Mic13 B (VDRC: 100911), Mic10 A (VDRC: 102479), 555 APOO(L) A (VDRC: 31098), Sam50 A (VDRC: 33641), Sam50 B (VDRC: 33642) 556 CHCHD<sup>D1</sup> was kindly shared by the Ge lab (Deng et al., 2016).

557 Assessment of lethality in co-KD of CHCHD3/6 and Cdk12 refers to percentage of 558 surviving flies at 1 week-of-age, versus the number of flies eclosed on day 0.

# 559 In situ heartbeat analysis

560 An *in-situ* dissection approach was used to expose the denervated beating fly heart 561 (Martin Fink et al., 2009; Ocorr et al., 2009; Vogler and Ocorr, 2009). SOHA (Semi-562 automated optical heartbeat analysis) was used to analyze high speed video recordings 563 to determine heart-related parameters (Martin Fink et al., 2009). Flies (n>15) were briefly 564 anesthetized using filter paper with 10µm FlyNap and transferred to a 10 X 35mm Petri 565 dish with Vaseline to attach the hydrophobic wing cuticle to the dish. Oxygenated room 566 temperature artificial hemolymph (108mM NaCl, 5mM KCl, 2mM CaCl<sub>2</sub>•2H<sub>2</sub>O, 8mM 567 MgCl<sub>2</sub>•6H<sub>2</sub>O, 15mM pH 7.1 HEPES, 1mM NaH<sub>2</sub>PO<sub>4</sub>•H<sub>2</sub>O, 4mM NaHCO<sub>3</sub>, 10mM sucrose, 568 and 5mM trehalose) was added to each dish. Flies were dissected as per(Vogler and 569 Ocorr, 2009) and oxygenated for minimum 15 minutes to equilibrate. Dissected flies were

570 filmed for 30 seconds using an Olympus BX63 microscope (10X magnification), a 571 Hamamatsu C11440 ORCA-flash4.0 OLT digital camera, and HCImageLive program. 572 These videos were uploaded to SOHA (semi-automated optical heartbeat analysis), end 573 diastolic and end systolic diameters were manually marked towards end of ostia, and 574 heart-related parameters were extracted (Fink *et al.*, 2009).

#### 575 In vivo heartbeat analysis

576 Norland #61 optical glue was placed on a 22 X 50mm coverslip (one small drop 577 for each fly). Flies (n>15) were briefly anesthetized using filter paper with 10µm FlyNap. 578 transferred to coverslip on individual adhesive drops with the dorsal side facing the 579 coverglass, and cured for 30 seconds using ultraviolet light. The coverslip was then 580 placed on a 10 X 35mm Petri dish and secured using putty. Fly hearts were filmed for 5 581 seconds using an Olympus BX63 microscope (20X magnification), a Hamamatsu C11440 582 ORCA-flash4.0LT digital camera, and HCImage Live program. All analysis was 583 automatically processed using R (Vogler, 2021)(gvogler/FlyHearts-tdtK-Rscripts: First 584 release of the R tdtK script. (Zenodo, 2021). doi:10.5281/zenodo.4749935.).

#### 585 Adult Drosophila heart immunohistochemistry

586 Flies were dissected as per (Vogler and Ocorr, 2009) in a 10 X 35mm Petri dish 587 and EGTA was added to a final concentration of 10mM. EGTA was removed and replaced 588 with 4% methanol-free formaldehyde for 20 minutes. Formaldehyde was removed and 589 replaced with 1X PBS 3 times. Flies thoraxes were removed, abdominal walls were 590 trimmed, and excess fat around heart was removed. Hearts were then washed 3 times 591 with 0.3% PBTx (Triton-X) for 15 minutes on a shaker. PBTx was removed and replaced 592 with 200µL 1° antibody solution (0.3% PBTx + 1° antibody), then a small piece of Parafilm 593 with carefully placed over the solution to form and seal of liquid over the hearts. Dishes 594 were incubated either 1) at 4°C overnight or 2) at room temperature for 2 hours while 595 shaking. Once finished incubating, Parafilm was gently removed with forceps and 3 15-596 minute washes with 0.3% PBTx were performed. PBTx was removed and replaced with 597 200µL 2° antibody solution (0.3% PBTx + 2° antibody), then a small piece of Parafilm was 598 carefully placed over the solution. Dishes were incubated either 1) at 4°C overnight or 2) 599 at room temperature for 2 hours while shaking. Parafilm was gently removed with forceps 600 and 3 15-minute washes with 0.3% PBTx were performed. PBTx was removed and 601 replaced with 1X PBS. Ventral cuticle with attached hearts were carefully removed 602 individually from the Vaseline layer and transferred to a 25 X 75 X 1mm slide with 2 18 X 603 18mm No. 1 coverslips glued to form a bridge and ProLong Gold antifade mounting 604 medium (Invitrogen) in the middle. Flies were placed ventral side up and covered with a 605 18 X 18mm No. 1.5 coverslip, sealed with clear nail polish around the edges, and stored 606 at room temperature for 24 hours until being moved to 4°C.

Primary Antibodies: anti-dMef2 (1:20, gift from Dr. Bruce Paterson); anti-slit (1:40,
c555 DSHB); anti-Myosin (1:50, 3E8-3D3 DSHB); anti-Sallimus (1:100, Abcam); antiATP5A (1:100, Abcam 14748); anti-ATP5A1 (1:200, Invitrogen 43-9800). All Secondaries
from Jackson Immuno Research Labs used at 1:500: Goat anti-Rat 594; Goat anti-Rabbit
647; Goat anti-Rabbit Cy5; Goat anti-mouse Cy3. Dyes: Phallodin 594 or 647 (1:100,
Invitrogen).

# 613 Drosophila indirect flight muscle dissection and immunofluorescence

614 Thoraxes were removed under light  $CO_2$  pressure and fixed for 40 minutes in 5% 615 PFA, followed by three 2-minute PBS washes. IFM muscle fibers were removed using 616 fine (#55) forceps and washed with 0.5% PBTx for 15 minutes, then washed with 0.1% 617 PBTx twice for 15 minutes. All subsequent antibody stainings were diluted in 0.1% PBTx 618 and incubated shaking at 4°C overnight to penetrate the muscle tissue. IFMs were 619 transferred to a 25 X 75 X 1mm slide without a bridge. ProLong Gold antifade mounting 620 medium (Invitrogen) was added, the samples were covered with a 18 X 18mm No. 1.5 621 coverslip, and sealed with clear nail polish around the edges.

#### 622 Drosophila embryo collection, fixation, and immunofluorescence

Adult flies were reared in a plastic bottle cage with a Petri dish on the bottom containing grape agar (Agar, EtOH, glacial acetic acid, grape juice) and yeast paste (yeast and  $H_2O$ ) at 25°C. After incubating (16 hours), embryos were carefully collected with a brush and placed in a mesh basket. Flies were washed with water, then placed in bleach for 3 minutes, followed by 30 seconds of wash with water. Embryos were removed

628 from mesh and placed in a fixation solution (2 Heptane: 1 2X PBS: 1 10% formaldehyde) 629 for 25 minutes. Formaldehyde layer (bottom) was removed, replaced with 500µL MetOH, 630 vortexed, then the supernatant with vitelline membranes (middle layer) was removed, this 631 was repeated once more. Embryos were washed with MetOH (3 rinses, followed by 1 632 hour on rotator). Embryos were stored in fresh MetOH at -20°C. 1° antibody was added 633 and tube was placed on rotator at 4°C overnight. 1° was later removed using 3X15 minute 634 0.4% PBTx washes. PBTx was removed, replaced with 2° antibody (diluted in PBTx), and rotated for 2 hours. 2° was later removed using 3X15 minute 0.4% PBTx washes, then 635 636 left in PBS at 4°C. Since CHCHD<sup>D1</sup> and CHCHD<sup>DefA</sup> are both homozygous lethal at adult stages, each line was rebalanced over TM6b YFP (CHCHD<sup>D1</sup>/TM6b YFP and 637 638 CHCHD<sup>DefA</sup>/TM6b YFP). The YFP lines (CHCHD<sup>D1</sup>/TM6b YFP and CHCHD<sup>DefA</sup>/TM6b 639 YFP) were crossed out and embryos were selected against GFP to obtain only CHCHD<sup>D1</sup>/CHCHD<sup>DefA</sup> embryos. 640

## 641 Fixed sample imaging

Samples were imaged at 10X, 25X, or 40X magnification using a Zeiss Apotome.1
Imager Z1, a Hamamatsu C11440 ORCA-flash4.0 OLT digital camera, and Zeiss ZEN.
In order to obtain higher resolution, confocal microscopy was performed for all
immunohistochemistry experiments involving Mito::GFP and ATP synthase staining.

#### 646 Climbing assay

647 Flies were initially anesthetized using FlyNap, placed into 5 separate vials, and 648 counted for a total at week 0 for Control C females= 178, Control C males= 125, 649 CHCHD3/6 C females= 154, CHCHD3/6 C males= 112. Each week, flies were transferred 650 using a funnel to a clean longer tube with no food and these tubes were placed in a 651 Styrofoam cutout to hold the tubes for tapping. The vial holder was tapped down multiple 652 times until flies were at the base of the vial and then left to record the percentage of flies 653 which reached 10cm after 10 seconds. The vial holder was tapped down multiple time to 654 achieve biological replicates= 4 and different batches of genotypes were examined for 655 technical replicates= 5.

#### 656 Statistical analyses

All statistical analyses were performed using GraphPad Prism version 8.0.1 for Windows, GraphPad Software, San Diego, California USA, <u>www.graphpad.com</u>. Statistical tests used are stated in figure legends. T-tests were performed on most heart assays where only one variable was defined. For tdtK analyses, a ranked one-way ANOVA Kruskal–Wallis test was used. Combinatorial KD assays with MICOS subunits and *CHCHD3/6* loss-of-function in *Drosophila* were analyzed with two-way ANOVA.

663 **PCR** 

664 The *CHCHD<sup>D1</sup>* line was confirmed via PCR using primers CHCHDD1 F4: 665 ATATATCCGACGATGTGG and CHCHDD1 R4: AGCTCCTGGTTCATCTGG (Q5® 666 High-Fidelity 2X Master Mix New England Bio).

### 667 Quantitative real time polymerase chain reaction (qRT-PCR)

668 RNA was extracted using Qiagen miRNeasy® Mini Kit and cDNA was synthesized 669 with Qiagen QuantiTech® reverse transcription kit. gRT-PCR analysis was performed 670 using Roche FastStart Essential DNA Probes Master and Roche LightCycler® 96 with 2 671 biological replicates and 3 technical replicates. Data was analyzed in the LightCycler® 672 CHCHD3/6 F: GCTAGAGGAACTTCAAAGATGG, application. Primers include 673 CHCHD3/6 R: GGGATAGGAGGATACTTTCGG. **RP49** F: 674 GCTAAGCTGTCGCACAAATG, RP49 R: GTTCGATCCGTAACCGATGT.

#### 675 Human iPSC-derived cardiomyocyte proliferation assays

At day 25 of differentiation, human iPSC-derived cardiomyocytes (hiPSC-CMs) were dissociated with TrypLE Select 10X (Gibco) for up to 12 min and action of TrypLE was neutralized with RPMI supplemented with 10% FBS. Cells were resuspended in RPMI with 2% KOSR (Gibco) and 2% B27 50X with vitamin A (Life Technologies) supplemented with 2 μM Thiazovivin and plated at a density of 5.000 cells per well in a Matrigel-coated 384-well plate. hiPSC-CMs were then transfected with siRNA (Dharmacon) directed against each gene using lipofectamine RNAi Max (ThermoFisher).

Each siRNA was tested in quadruplicate. 48 hours post-transfection, cells were labeled
with 10 μM EdU (ThermoFisher). After 24h of EdU incubation, cells were fixed with 4%
paraformaldehyde for 30 minutes. EdU was detected according to the protocol and cells
were stained with cardiac specific marker ACTN2 (Sigma A7811, dilution 1:800) and
DAPI. Cells were imaged with ImageXpress Micro XLS microscope (Molecular Devices)
and custom algorithms were used to quantify EdU+ hiPSC-CMs.

# 689 ATP Measurements

690 Measurements of ATP were performed using a luciferase assay as described 691 previously (Liu and Lu, 2010; Zanon et al., 2017). 10-12 hearts per sample were collected 692 from 1-week old flies and homogenized in 100µl extraction buffer (100 mM Tris and 4 mM 693 EDTA, pH 7.8) containing 6M guanidine-HCI followed by rapid freezing in liquid nitrogen. 694 The samples were boiled for 5min and cleared by centrifugation at 14,000 x g. 695 Supernatants were diluted 1:50 and ATP levels were determined using ENLITEN® ATP 696 Assay System (Promega, Cat #FF2000) as per manufacturer instructions. Total protein 697 levels were determined by BCA method (Pierce, Cat #23225). ATP measurements were 698 normalized to protein.

#### 699 Hybridization Chain Reaction (HCR)

700 Hearts were exposed as described above and RNA in situ performed and analyzed as described in (Kirkland et al., 2021). Briefly, hearts were relaxed using 10mM EGTA in 701 702 artificial hemolymph and fixed in 4% formaldehyde in 0.1% Tween 20-PBS for 20 minutes. 703 Hearts were then washed with 0.1% Tween 20, PBS, 2 x 5 minutes. On ice, hearts were 704 incubated in a methanol gradient with PBS for 5 minutes each (25%, 50%, 75%, 100%, 705 75%, 50%, 25%). Hearts were then permeabilized in 1% Triton 100-X in PBS for 2 hours 706 at room temperature. The hearts were post-fixed with 4% formaldehyde in 0.1% Tween 707 20-PBS for 20 minutes at room temperature before washing on ice with 0.1% Tween 20-708 PBS, 2 x 5 minutes. Subsequently, samples were washed with 50% 0.1% Tween 20-PBS 709 and 50% 5XSSCT (5X SSC, 0.1% Tween 20, H<sub>2</sub>O) for 5 minutes on ice, followed by 5X 710 SSCT for another 5 minutes. The hearts were then transferred to a 96 well plate and the 711 hearts incubated in probe hybridization buffer (Molecular Instruments) for 5 minutes on

712 ice, then 30 minutes at 37°C. The solution was then replaced with 2µl of each probe in 713 200µl of probe hybridization buffer and incubated at 37°C overnight (up to 16 hours). 714 Next, 4 x 15 minute washes were performed with probe wash buffer (Molecular 715 Instruments) at 37° C, then 2 x 5 minute 5XSSCT and 1 x 5 minute amplification buffer 716 (Molecular Instruments). 2µl of corresponding h1 and h2 hairpins (Molecular Instruments) were heated to 95°C for 90 seconds, cooled in the dark for 30 minutes and added to 100µl 717 718 of amplification buffer. Hairpin solution was then incubated with the heart samples at room 719 temperature overnight (up to 16 hours), in the dark. Next, samples were washed 2 x 5 720 minutes with 5X SSCT; 2 x 30 minutes with 5X SSCT; 1 x 5 minutes with 5X SSCT and 721 rinsed 3 x with PBS. DAPI in PBS (1:500) was incubated with the samples for 15 minutes. 722 then samples were again rinsed 3 x 5 minutes in PBS. Samples were then mounted and 723 imaged as described above. To quantify expression, a maximum projection image was 724 created in ImageJ from the confocal stack image and binarized. The region around the 725 cardiomyocyte nucleus was traced and the ROI copied to the binary image for particle 726 analysis. Since segmentation was imperfect for transcripts very close together and to 727 account for differences in pocket size, the % area covered by the transcripts was used to 728 assess statistical significance in Prism (Graphpad).

729

730

731

#### 732 **REFERENCES**

- 733 Ackermann, A. and Brieger, A. (2019) 'The Role of Nonerythroid Spectrin αII in Cancer',
- 734 Journal of Oncology, 2019, pp. 1–14. doi: 10.1155/2019/7079604.
- Ahmad, S. M. (2017) 'Conserved signaling mechanisms in Drosophila heart
- development', *Developmental Dynamics*. John Wiley & Sons, Ltd, 246(9), pp. 641–656.
- 737 doi: https://doi.org/10.1002/dvdy.24530.
- Alston, C. L. *et al.* (2017) 'The genetics and pathology of mitochondrial disease', *Journal of Pathology*, pp. 236–250.
- 740 Altmann, K. et al. (2000) 'Two-Dimensional Echocardiographic Assessment of Right
- 741 Ventricular Function as a Predictor of Outcome in Hypoplastic Left Heart Syndrome',
- 742 The American Journal of Cardiology, 86, pp. 964–968.
- 743 Bartkowiak, B. et al. (2010) 'CDK12 is a transcription elongation-associated CTD
- kinase, the metazoan ortholog of yeast Ctk1', *Genes and Development*, 24(20), pp.
- 745 2303–2316. doi: 10.1101/gad.1968210.
- 746 Benson, G. (1999) 'Tandem repeats finder: a program to analyze DNA sequences',
- 747 *Nucleic acids research*, 27(2), pp. 573–580. doi: 10.1093/nar/27.2.573.
- 748 Bhandari, P., Song, M. and Dorn, G. W. (2015) 'Dissociation of mitochondrial from
- 749 sarcoplasmic reticular stress in Drosophila cardiomyopathy induced by molecularly
- 750 distinct mitochondrial fusion defects', *Journal of molecular and cellular cardiology*.
- 751 2014/12/30, 80(2), pp. 71–80. doi: 10.1016/j.yjmcc.2014.12.018.
- 752 Bier, E. and Bodmer, R. (2004) 'Drosophila, an emerging model for cardiac disease',
- 753 *Gene*, 342(1), pp. 1–11. doi: 10.1016/j.gene.2004.07.018.
- 754 Bodmer, R. (1995) 'Heart Development in Drosophila and its Relationship to
- 755 Vertebrates', *Trends Cardiovasc Med.*, 1738(94), pp. 21–28.
- 756 Bodmer, R. and Frasch, M. (2010) Development and Aging of the Drosophila Heart,
- 757 *Heart Development and Regeneration.* Elsevier Inc.
- 758 Brand, A. H. and Perrimon, N. (1993) 'Targeted gene expression as a means of altering
- cell fates and generating dominant phenotypes', *Development*. 1993/06/01, 118(2), pp.

- 760 401–415.
- 761 Carlier, M. (1998) 'Control of actin dynamics', *Current Opinion in Cell Biology*, 132, pp.762 45–51.
- 763 Carlier, M. F., Pantaloni, D. and Korn, E. D. (1984) 'Evidence for an ATP cap at the
- regulation of the F-actin steady state', Journal of
- 765 *Biological Chemistry*, 259(16), pp. 9983–9986. doi: 10.1016/s0021-9258(18)90914-2.
- 766 Cogliati, S., Enriquez, J. A. and Scorrano, L. (2016) 'Mitochondrial Cristae: Where
- 767 Beauty Meets Functionality', *Trends in Biochemical Sciences*. Elsevier Ltd, 41(3), pp.
- 768 261–273. doi: 10.1016/j.tibs.2016.01.001.
- 769 Cripps, R. M. and Olson, E. N. (2002) 'Control of Cardiac Development by an
- 770 Evolutionarily Conserved Transcriptional Network', Developmental Biology, 28, pp. 14–
- 771 28. doi: 10.1006/dbio.2002.0666.
- 772 Crucean, A. et al. (2017) 'Re-evaluation of hypoplastic left heart syndrome from a
- 773 developmental and morphological perspective', Orphanet Journal of Rare Diseases.
- 774 Orphanet Journal of Rare Diseases, 12(1), pp. 1–10. doi: 10.1186/s13023-017-0683-4.
- 775 Darshi, M. et al. (2011) 'ChChd3, an inner mitochondrial membrane protein, is essential
- for maintaining Crista integrity and mitochondrial function', *Journal of Biological*
- 777 *Chemistry*, 286(4), pp. 2918–2932. doi: 10.1074/jbc.M110.171975.
- 778 Deng, Q. et al. (2016) 'Cross-talk between mitochondrial fusion and the Hippo pathway
- in controlling cell proliferation during Drosophila development', *Genetics*, 203(4), pp.
- 780 1777–1788. doi: 10.1534/genetics.115.186445.
- 781 Ding, C. et al. (2015) 'Mitofilin and CHCHD6 physically interact with Sam50 to sustain
- ristae structure', *Scientific Reports*. Nature Publishing Group, 5, pp. 1–11. doi:
- 783 10.1038/srep16064.
- Fink, Martin *et al.* (2009) 'A new method for detection and quantification of heartbeat
- parameters in Drosophila, zebrafish, and embrtonic mouse hearts', 46(2), pp. 101–113.
- 786 doi: 10.2144/000113078.A.
- Fink, M et al. (2009) 'A new method for detection and quantification of heartbeat

- parameters in Drosophila, zebrafish, and embryonic mouse hearts', *Biotechniques*.
- 789 2009/03/26, 46(2), pp. 101–113. doi: 10.2144/000113078.
- 790 Friedman, J. R. et al. (2015) 'MICOS coordinates with respiratory complexes and lipids
- to establish mitochondrial inner membrane architecture', *eLife*. Edited by R. J. Youle.
- eLife Sciences Publications, Ltd, 4, p. e07739. doi: 10.7554/eLife.07739.
- 793 Gaber, N. et al. (2013) 'Fetal Reprogramming and Senescence in Hypoplastic Left
- 794 Heart Syndrome and in Human Pluripotent Stem Cells during Cardiac Differentiation',
- 795 The American Journal of Pathology. Elsevier, 183(3), pp. 720–734. doi:
- 796 10.1016/j.ajpath.2013.05.022.
- 797 Garg, V. et al. (2005) 'Mutations in NOTCH1 cause aortic valve disease', Nature,
- 798 437(September), pp. 1–5. doi: 10.1038/nature03940.
- 799 Goldberg, D. J. and Rychik, J. (2016) 'Hypoplastic Left Heart Syndrome', in
- 800 Echocardiography in Pediatric and Congenital Heart Disease: From Fetus to Adult:
- 801 Second Edition, pp. 357–381. doi: 10.1002/9781118742440.ch20.
- 802 Grossfeld, P. et al. (2019) 'Hypoplastic Left Heart Syndrome: A New Paradigm for an
- 803 Old Disease?', *Journal of Cardiovascular Development and Disease*, 6(1), pp. 1–13.
- 804 doi: 10.3390/jcdd6010010.
- Han, Z. et al. (2006) 'Hand, an evolutionarily conserved bHLH transcription factor
- required for Drosophila cardiogenesis and hematopoiesis', *DEVELOPMENT AND DISEASE*, 1182, pp. 1175–1182. doi: 10.1242/dev.02285.
- 808 Han, Z. and Olson, E. N. (2005) 'Hand is a direct target of Tinman and GATA factors
- 809 during Drosophila cardiogenesis and hematopoiesis', *Development*, 132(15), pp. 3525–
- 810 3536. doi: 10.1242/dev.01899.
- 811 Hu, Y. et al. (2011) 'An integrative approach to ortholog prediction for disease-focused
- and other functional studies', *BMC Bioinformatics*, 12(357), pp. 1–16. doi:
- 813 10.1186/1471-2105-12-357.
- Jin, S. C. et al. (2017) 'Contribution of rare inherited and de novo variants in 2,871
- 815 congenital heart disease probands', *Nature Genetics*, 49(11), pp. 1593–1601. doi:
- 816 10.1038/ng.3970.

- 817 Karczewski, K. J. et al. (2020) 'The mutational constraint spectrum quantified from
- 818 variation in 141,456 humans', *Nature*, 581(7809), pp. 434–443. doi: 10.1038/s41586-

819 020-2308-7.

- 820 Kimbrell, D. A. *et al.* (2002) 'The Dorothy Enhancer Has Tinman Binding Sites and
- Drives hopscotch -Induced Tumor Formation', 28, pp. 23–28. doi: 10.1002/gene.10134.
- 822 Kirkland, N. et al. (2021) 'Age-dependent Lamin remodeling induces cardiac dysfunction
- 823 via dysregulation of cardiac transcriptional programs'. Available at:
- 824 https://doi.org/10.21203/rs.3.rs-1021378/v1.
- 825 Klassen, M. P. et al. (2017) 'Age-dependent diastolic heart failure in an in vivo

826 Drosophila model', *eLife*, 6, pp. 1–22. doi: 10.7554/eLife.20851.

- 827 Kobayashi, J. et al. (2014) 'Directed Differentiation of Patient-Specific Induced
- 828 Pluripotent Stem Cells Identifies the Transcriptional Repression and Epigenetic
- 829 Modification of NKX2-5, HAND1, and NOTCH1 in Hypoplastic Left Heart Syndrome',
- 830 *PLoS ONE*, 9(7), pp. 1–14. doi: 10.1371/journal.pone.0102796.
- 831 Korn, E. D., Carlier, M. F. and Pantaloni, D. (1987) 'Actin polymerization and ATP
- hydrolysis', *Science*, 238(4827), pp. 638–644. doi: 10.1126/science.3672117.
- 833 Kozjak-Pavlovic, V. (2017) 'The MICOS complex of human mitochondria', Cell and
- *Tissue Research*. Cell and Tissue Research, pp. 83–93. doi: 10.1007/s00441-016-
- 835 2433-7.
- Li, H. et al. (2016) 'Mic60/Mitofilin determines MICOS assembly essential for
- 837 mitochondrial dynamics and mtDNA nucleoid organization', *Cell Death and*
- 838 *Differentiation*, 23(3), pp. 380–392. doi: 10.1038/cdd.2015.102.
- Liu, S. and Lu, B. (2010) 'Reduction of Protein Translation and Activation of Autophagy
- 840 Protect against PINK1 Pathogenesis in Drosophila melanogaster', *PLOS Genetics*.
- 841 Public Library of Science, 6(12), p. e1001237. Available at:
- 842 https://doi.org/10.1371/journal.pgen.1001237.
- Liu, X. et al. (2017) 'The complex genetics of hypoplastic left heart syndrome', Nat
- 844 *Genet.*, 49(7), pp. 1152–1159. doi: 10.1038/ng.3870.The.

- Lo, P. C. H. and Frasch, M. (2001) 'A role for the COUP-TF-related gene seven-up in
- the diversi ® cation of cardioblast identities in the dorsal vessel of Drosophila', 104, pp.49–60.
- 848 Marian, A. J. and Belmont, J. (2011) 'Strategic approaches to unraveling genetic causes
- of cardiovascular diseases', *Circulation Research*, 108(10), pp. 1252–1269. doi:
- 850 10.1161/CIRCRESAHA.110.236067.
- 851 Martínez-Morentin, L. *et al.* (2015) 'Cardiac deficiency of single cytochrome oxidase
- assembly factor scox induces p53-dependent apoptosis in a Drosophila cardiomyopathy
- 853 model', *Human Molecular Genetics*, 24(13), pp. 3608–3622. doi: 10.1093/hmg/ddv106.
- 854 Mcbride, K. L. et al. (2008) 'NOTCH1 mutations in individuals with left ventricular
- 855 outflow tract malformations reduce ligand-induced signaling', *Human Molecular*
- 856 *Genetics*, 17(18), pp. 2886–2893. doi: 10.1093/hmg/ddn187.
- 857 McKenna, A. *et al.* (2010) 'The Genome Analysis Toolkit: a MapReduce framework for
- 858 analyzing next-generation DNA sequencing data', Genome research. 2010/07/19. Cold
- 859 Spring Harbor Laboratory Press, 20(9), pp. 1297–1303. doi: 10.1101/gr.107524.110.
- 860 Mussa, S. and Barron, D. J. (2017) 'Hypoplastic left heart syndrome', *Paediatrics and*
- 861 *Child Health*, 27(2), pp. 75–82. doi: https://doi.org/10.1016/j.paed.2016.12.002.
- 862 Ocorr, K. et al. (2009) 'Semi-automated Optical Heartbeat Analysis of small hearts',
- *Journal of visualized experiments : JoVE*. MyJove Corporation, (31), p. 1435. doi:
- 864 10.3791/1435.
- 865 Ott, C. et al. (2012) 'Sam50 functions in mitochondrial intermembrane space bridging
- and biogenesis of respiratory complexes.', *Molecular and cellular biology*, 32(6), pp.
- 867 1173–1188. doi: 10.1128/MCB.06388-11.
- Paige, S. *et al.* (2020) 'Patient-specific induced pluripotent stem cells implicate intrinsic
  impaired contractility in hypoplastic left heart syndrome', *Circulation*, pp. 1605–1608.
- 870 Palikaras, K., Lionaki, E. and Tavernarakis, N. (2015) 'Coupling mitogenesis and
- 871 mitophagy for longevity', *Autophagy*, 11(8), pp. 1428–1430. doi:
- 872 10.1080/15548627.2015.1061172.

- 873 Palikaras, K. and Tavernarakis, N. (2014) 'Mitochondrial homeostasis: The interplay
- 874 between mitophagy and mitochondrial biogenesis', *Experimental Gerontology*. Elsevier
- 875 Inc., 56, pp. 182–188. doi: 10.1016/j.exger.2014.01.021.
- 876 Pandey, U. B. and Nichols, C. D. (2011) 'Human Disease Models in Drosophila
- 877 melanogaster and the Role of the Fly in Therapeutic Drug Discovery', Drug Delivery,
- 878 63(2), pp. 411–436. doi: 10.1124/pr.110.003293.411.
- 879 Poplin, R. *et al.* (2018) 'Scaling accurate genetic variant discovery to tens of thousands
- of samples', *bioRxiv*, p. 201178. doi: 10.1101/201178.
- 881 Raney, B. J. et al. (2014) 'Track data hubs enable visualization of user-defined genome-
- wide annotations on the UCSC Genome Browser', *Bioinformatics (Oxford, England)*.
- 883 2013/11/13. Oxford University Press, 30(7), pp. 1003–1005. doi:
- 884 10.1093/bioinformatics/btt637.
- Ranganayakulu, G. *et al.* (2010) 'Divergent roles for NK-2 class homeobox genes in
  cardiogenesis in flies and mice', 3048(1998), pp. 3037–3048.
- Romanello, V. and Sandri, M. (2016) 'Mitochondrial quality control and muscle mass
  maintenance', *Frontiers in Physiology*, pp. 1–21.
- Sun, N., Youle, R. J. and Finkel, T. (2016) 'The Mitochondrial Basis of Aging', *Molecular cell*, 61(5), pp. 654–666. doi: 10.1016/j.molcel.2016.01.028.
- 891 Tang, J. et al. (2020) 'Sam50–Mic19–Mic60 axis determines mitochondrial cristae
- architecture by mediating mitochondrial outer and inner membrane contact', *Cell Death*
- and Differentiation. Springer US, 27(1), pp. 146–160. doi: 10.1038/s41418-019-0345-2.
- 894 Tchervenkov, C. I. et al. (2006) 'The nomenclature, definition and classification of
- hypoplastic left heart syndrome', *Cardiology in the Young*, 16(4), pp. 339–368. doi:
- 896 10.1017/S1047951106000291.
- 897 Theis, J. L., Hrstka, S. C. L., et al. (2015) 'Compound heterozygous NOTCH1 mutations
- underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome',
- 899 Human Genetics. Springer Berlin Heidelberg, 134(9), pp. 1003–1011. doi:
- 900 10.1007/s00439-015-1582-1.

- 901 Theis, J. L., Zimmermann, M. T., et al. (2015) 'Recessive MYH6 Mutations in
- 902 Hypoplastic Left Heart With Reduced Ejection Fraction.', *Circulation. Cardiovascular*
- 903 *genetics*. United States, 8(4), pp. 564–571. doi: 10.1161/CIRCGENETICS.115.001070.
- 904 Theis, J. L. *et al.* (2020) 'Patient-specific genomics and cross-species functional
- analysis implicate LRP2 in hypoplastic left heart syndrome', *eLife*. Edited by D. Y. R.
- 906 Stainier, A. Ebert, and L. Kochilas. eLife Sciences Publications, Ltd, 9, p. e59554. doi:
- 907 10.7554/eLife.59554.
- 908 Theis, J. L. *et al.* (2021) 'Genetic Association Between Hypoplastic Left Heart Syndrome
- 909 and Cardiomyopathies', *Circulation: Genomic and Precision Medicine*. American Heart
- 910 Association, 14(1), p. e003126. doi: 10.1161/CIRCGEN.120.003126.
- 911 Theis, J. L. et al. (2022) 'CELSR1 Risk Alleles in Familial Bicuspid Aortic Valve and
- 912 Hypoplastic Left Heart Syndrome', *Circulation: Genomic and Precision Medicine*.
- 913 American Heart Association, 15(2), p. e003523. doi: 10.1161/CIRCGEN.121.003523.
- 914 Theis, J. L. and Olson, T. M. (2022) 'Whole Genome Sequencing in Hypoplastic Left
- 915 Heart Syndrome', Journal of Cardiovascular Development and Disease . doi:
- 916 10.3390/jcdd9040117.
- 917 Tocchi, A. et al. (2015) 'Mitochondrial dysfunction in cardiac aging', Biochimica et
- 918 Biophysica Acta Bioenergetics. Elsevier B.V., 1847(11), pp. 1424–1433. doi:
- 919 10.1016/j.bbabio.2015.07.009.
- 920 Tomita-mitchell, A. *et al.* (2016) 'Impact of MYH6 variants in hypoplastic left heart
- 921 syndrome', *Physiological Genomics*. American Physiological Society, 48(12), pp. 912–
- 922 921. doi: 10.1152/physiolgenomics.00091.2016.
- 923 Ugur, B., Chen, K. and Bellen, H. J. (2016) 'Drosophila tools and assays for the study of
- human diseases', *DMM Disease Models and Mechanisms*, 9(3), pp. 235–244. doi:
- 925 10.1242/dmm.023762.
- 926 Vogler, G. (2021) 'gvogler/FlyHearts-tdtK-Rscripts: First release of the R tdtK script.'
- 927 Zenodo. doi: 10.5281/zenodo.4749935.
- 928 Vogler, G. et al. (2021) 'Single-cell sequencing of the <em&gt;Drosophila&lt;/em&gt;
- 929 embryonic heart and muscle cells during differentiation and maturation', *bioRxiv*, p.

- 930 2021.01.15.426556. doi: 10.1101/2021.01.15.426556.
- Vogler, G. and Ocorr, K. (2009) 'Visualizing the beating heart in Drosophila', *Journal of*
- 932 visualized experiments : JoVE. MyJove Corporation, (31), p. 1425. doi: 10.3791/1425.
- 933 Xie, H. B. et al. (2013) 'The NADPH Metabolic Network Regulates Human a B- crystallin
- 934 Cardiomyopathy and Reductive Stress in Drosophila melanogaster', 9(6). doi:
- 935 10.1371/journal.pgen.1003544.
- 936 Xu, X. *et al.* (1998) 'Smad proteins act in combination with synergistic and antagonistic
- 937 regulators to target Dpp responses to the Drosophila mesoderm', Genes and
- 938 *Development*, 12(15), pp. 2354–2370. doi: 10.1101/gad.12.15.2354.
- 939 Yagi, H. et al. (2018) 'The Genetic Landscape of Hypoplastic Left Heart Syndrome',
- 940 *Pediatric cardiology*. United States: Springer US, 39(6), pp. 1069–1081. doi:
- 941 10.1007/s00246-018-1861-4.
- 942 Yamazaki, Y. et al. (2013) 'Goliath family E3 ligases regulate the recycling endosome
- pathway via VAMP3 ubiquitylation', *EMBO Journal*, 32(4), pp. 524–537. doi:
- 944 10.1038/emboj.2013.1.
- 945 Yang, C. et al. (2017) 'Induced pluripotent stem cell modelling of HLHS underlines the
- 946 contribution of dysfunctional NOTCH signalling to impaired cardiogenesis', *Human*
- 947 *Molecular Genetics*, 26(16), pp. 3031–3045. doi: 10.1093/hmg/ddx140.
- Ye, M. *et al.* (2009) 'Deletion of ETS-1, a gene in the Jacobsen syndrome critical region,
  causes ventricular septal defects and abnormal ventricular morphology in mice', *Human Molecular Genetics*, 19(4), pp. 648–656. doi: 10.1093/hmg/ddp532.
- 951 Yin, Z., Xu, X. L. and Frasch, M. (1997) 'Regulation of the twist target gene tinman by
  952 modular cis-regulatory elements during early mesoderm development', *Development*,
  953 104(24) and 4074 4020 data 4040/data 404 24 4074
- 953 124(24), pp. 4971–4982. doi: 10.1242/dev.124.24.4971.
- 254 Zanon, A. *et al.* (2017) 'SLP-2 interacts with Parkin in mitochondria and prevents
- 955 mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and
- 956 Drosophila', *Human molecular genetics*. Institute for Biomedicine, Eurac Research,
- 957 Affiliated Institute of the University of Lübeck, 39100 Bolzano, Italy., 26(13), pp. 2412–
- 958 2425. doi: 10.1093/hmg/ddx132.

- 959 Zhang, J. et al. (2019) 'Cardiomyocyte-specific loss of RNA polymerase II subunit 5-
- 960 mediating protein causes myocardial dysfunction and heart failure', *Cardiovascular*
- 961 *Research*, 115(11), pp. 1617–1628. doi: 10.1093/cvr/cvy307.

962

963

#### 964 Figure legends

965 Figure 1: Prioritization of CHCHD6 in HLHS proband and its Drosophila ortholog 966 CHCHD3/6. A) Pedigree of index family 11H. The family includes consanguineous 967 parents (denoted by double horizontal lines) without cardiac defects, one son with HLHS 968 (proband), and two siblings without cardiac defects. B) List of 9 candidate genes derived 969 from proband 11H with corresponding Drosophila orthologs. Orthology based on DIOPT 970 score. Conserved Drosophila candidate HLHS genes were knocked down individually in 971 the Drosophila heart using the Hand<sup>4.2</sup>-Gal4 driver. The functional phenotypes listed were 972 significantly different relative to Control<sup>A</sup> or Control<sup>B</sup> and were measured in 1-week old 973 female Drosophila hearts. C) Schematic of Drosophila highlighting the abdominal region 974 which includes the heart tube and flanking pericardial cells, where the Hand<sup>4.2</sup>-Gal4 driver 975 is expressed. Image adapted from (Xie et al., 2013). D) End-Diastolic diameter (EDD), E) 976 End-systolic diameter (ESD), and F) fractional shortening (FS) from 1-week old female Hand<sup>4.2</sup>-Gal4 >CHCHD3/6 flies. 977

978 Supp. Figure 1: CHCHD3/6 KD in the Drosophila heart causes reduced fractional 979 shortening due to systolic dysfunction. A) EDD, B) ESD and C) FS from 3-week old 980 Hand<sup>4.2</sup>>CHCHD3/6 female flies. Very low number of Hand<sup>4.2</sup>>CHCHD3/6<sup>RNAiB</sup> flies 981 reaching 3 weeks-of-age indicates lethality possibly due to stronger KD of CHCHD3/6. D-982 F) 1-week old Hand<sup>4.2</sup>-Gal4, tdtK>CHCHD3/6 female flies measured for D) EDD, E) ESD 983 and F) FS. G) Confocal images of CHCHD3/6 mRNA and tinman mRNA (top) and 984 processed images (bottom) using a custom ImageJ macro. H-I) CHCHD3/6 and tinman 985 mRNA in 1-week old female Drosophila hearts. H) CHCHD3/6 mRNA relative to tinman 986 mRNA is reduced in Hand<sup>4.2</sup>>CHCHD3/6<sup>RNAiA</sup> heart tissue. I) tinman mRNA % area, used 987 as marker to normalize expression to. Fractional shortening in control and CHCHD3/6 KD 988 female flies at 3 weeks of age with a J) pericardial cell-specific driver (DOT-Gal4), K) all 989 muscle cell specific driver (Mef2-Gal4), and L) neuronal driver (elav-Gal4). Note that *Mef2>CHCHD3/*6<sup>RNAiA</sup> 990 was lethal at pupal stages. M) Fractional shortening measurements from Hand<sup>4.2</sup>>DUOX<sup>RNAiC</sup> 3-week old flies. Unpaired two-tailed t-test, 991 \*p≤0.05, \*\*p≤0.01, \*\*\*p≤ 0.001, \*\*\*\*p≤ 0.0001; error bars represent SEM. 992

993 Supplementary Table 1: Prioritized candidate genes from HLHS proband. Nine 994 candidate genes harbored rare homozygous variants predicted to impact protein structure 995 or gene regulation. Chr = chromosome, CADD = combined annotation dependent 996 depletion, Hom = homozygous, Het = heterozygous, WT = wildtype, gnomAD = Genome 997 Aggregation Database, MAF = minor allele frequency.

998 Figure 2: CHCHD3/6 expression is important for adult cardiac function around 999 larval stages and early adult stages. A) UMAP (uniform manifold approximation and 1000 projection) plot from CB-specific single-cell transcriptionics (Vogler et al., 2021) showing 1001 expression of CHCHD3/6 in CBs, as identified by cardiac TFs tin, H15, and Hand. B) 1002 Stage 16-17 embryos (late stage cardiogenesis) were collected from a CHCHD3/6 loss 1003 of function line (CHCHD<sup>D1</sup>) line crossed to a CHCHD3/6 deficiency line (CHCHD<sup>DefA</sup>) and 1004 stained for Mef2 (all muscle transcription factor, magenta) and Slit (secreted protein of the lumen, green). 50µm scale. C) tinD>Control<sup>A</sup> or >CHCHD3/6<sup>RNAiA</sup> were reared at 29°C 1005 1006 and females were filmed and imaged at 1-week of age. A) *tinD*>CHCHD3/6<sup>RNAiA</sup> did not 1007 have a significant reduction in fractional shortening compared to *tinD*>Control<sup>A</sup> flies. D) 1008 F-actin was unchanged between *tinD*>Control<sup>A</sup> and *tinD*>CHCHD3/6<sup>RNAiA</sup> flies at 1 week 1009 of age; 20µm scale. E) Schematic overview of temperature shift experiments. F-I) 1010 Fractional shortening measurements from 1-week old female flies reared at F) 19°C for 1011 whole life, G) at 29°C for whole life, H) 19°C, and moved to 29°C at early pupal stages, 1012 or I) 19 °C, and moved to 29°C once eclosed (virgin flies), Unpaired two-tailed t-test, 1013 \*\*\*\*p≤ 0.0001, error bars represent SEM.

1014 Figure 3: Cardiac tissue from heart-specific CHCHD3/6 KD flies exhibit reduced and 1015 altered sarcomeric proteins in the myocardial tissue. A) Schematic of sarcomeric 1016 protein distribution inside myofibrils (image created with BioRender.com). B) F-actin staining in 1-week old female Drosophila hearts with Hand<sup>4.2</sup>-Gal4 KD of CHCHD3/6. 1017 1018 Arrowheads indicate ostial myofibrils and arrows point to myocardial myofibrils (non-1019 ostial). C) F-actin intensity measured as mean gray value (gray value/# of pixels) along 1020 myocardial myofibrils relative to mean gray value of ostial myofibrils. D) Mean intensity of F-actin along individual myofibrils. 1-week old Drosophila hearts with Hand<sup>4.2</sup>-Gal4 driven 1021 1022 KD of control or CHCHD3/6 stained for antibodies against E) Myosin, F) Obscurin, G) α-

Actinin, or **H)** Sallimus. Arrowheads indicate ostial myofibrils and arrows point to working cardiomyocyte tissue (non-ostial). **I-L)** Mean fluorescence intensity along myocardial myofibrils relative to ostia myofibrils in 1-week old  $Hand^{4.2}$ -*Gal4*>CHCHD3/6<sup>RNAiA</sup> adults stained for sarcomeric proteins **I)** Myosin, **J)** Obscurin, **K)** α-Actinin, or **L)** Sallimus. Unpaired two-tailed t-test, \*\*p≤0.01, \*\*\*\*p≤0.0001; error bars represent SEM. 20µm scale.

1028 **Supp. Figure 2: A-C)** Candidate genes involved in polymerization/de-polymerization of 1029 F-actin phenotypes upon KD using a  $Hand^{4.2}$ -Gal4;tdtK<sup>attP2</sup> driver, measured at 1-week of 1030 age. **D)** Fractional shortening from RNAi<sup>A</sup> lines. **E)** F-actin phenotype of hits **C)**. 20µm 1031 scale. Unpaired two-tailed t-test, \*p≤0.05, \*\*p≤0.01; error bars represent SEM. FS= 1032 fractional shortening, DD= End diastolic diameter, SD= Systolic diameter.

1033 Figure 4: Mitochondria are aggregated and show reduced Complex IV and V 1034 staining upon loss of CHCHD3/6. Visualization of F-actin and mitochondria in 1035 Drosophila indirect flight muscles (IFMs). A-E) 1-2 day-old male Drosophila IFMs with 1036 Mito::GFP; Mef2-Gal4 stained for A) F-actin, B) GFP (Mito::GFP (GFP tagged COX8A)), 1037 **C)** ATP synthase, **D)** merged image of B + C, and **E)** merged image of A + B,10µm scale. F) Hand<sup>4.2</sup>>CHCHD3/6<sup>RNAiA</sup> heart tissue at 1-week of age. G-I) F-actin and Mito::GFP 1038 1039 staining in 1-week old female hearts using the Hand<sup>4.2</sup>-Gal4; Mito::GFP driver, 20µm 1040 scale. J-L) Hand<sup>4.2</sup>-Gal4; tdtK driven KD of ATP synthase subunits at 1-week of age 1041 measuring J) diastolic diameter, K) systolic diameter, and L) fractional shortening. Data is plotted as  $\pm$  SEM and significance indicated relative to Control<sup>GD2</sup>. \*\*\*\**P*  $\leq$  0.0001, 1042 1043 \*\* $P \le 0.01$ . **M**) 1-week old Hand<sup>4.2</sup>-Gal4; tdtK driven KD of ATP synthase subunits with 1044 altered F-actin (CHCHD3/6 KD is depicted to contrast the structural phenotypes). N) 1045 Quantification of ATP levels from hearts of 1-week old flies (10-12 hearts per sample). 1046 ATP measurements were plotted relative to protein content. Statistical differences were 1047 calculated by one-way ANOVA followed by Tukey's post hoc test for multiple 1048 comparisons.

**Supplementary Table 2: Mitochondrial gene screen in the** *Drosophila* heart. RNAi lines of different mitochondrial functional groups were selected using the FlyBase.org gene ontology (GO) term mitochondrion (GO:0005739). The RNAi lines were crossed to *Hand*<sup>4.2</sup>-*Gal4*, tdtK and their progeny were assessed for contractility defects at 1-week of

adult age using *Hand<sup>4.2</sup>-Gal4*; tdtK. Note that structural phenotype refers to any visible Factin phenotype, not specifically to *CHCHD3/6* KD F-actin phenotype. FS= fractional
shortening, DD= End diastolic diameter, SD= systolic diameter.

1056 Supp. Figure 3: A) KD of mitochondrial ATP synthase subunits using Hand<sup>4.2</sup>-Gal4; tdtK 1057 produced strong F-actin phenotypes. 20µm scale. B-C) CHCHD3/6 was knocked down 1058 using a Mito::GFP; Mef2-Gal4 line; note that Mito::GFP; Mef2-Gal4>CHCHD3/6<sup>RNAiA</sup> is pupal lethal. B) Viability was significantly reduced in male and female CHCHD3/6<sup>RNAiC1</sup> 1059 1060 flies over a 4-week time course. Mantel-Cox test. C) Negative Geotaxis assay (average 1061 number of flies above a 10cm mark after being tapped down in a long vial) measured in 1062 1-week old male and female flies. Unpaired two-tailed t-test, \*\*\*\*p≤ 0.0001; error bars 1063 represent SEM.

1064 Figure 5: Assessment of other MICOS subunits in the Drosophila heart and in 1065 VCMs. A) Schematic of the MICOS complex and SAM50. Human MICOS subunits and 1066 their respective Drosophila homologs are listed (image created with BioRender.com). B) 1067 fractional shortening measured from 1-week old female flies with KD of individual MICOS 1068 subunits and Sam50 using a Hand<sup>4.2</sup>-Gal4 driver. Unpaired two-tailed t-test, \*\*\* $p \le 0.001$ , 1069 \*\*\*\*p  $\leq$  0.0001; error bars represent SEM. C) Hand<sup>4.2</sup>-Gal4, tdtK; CHCHD<sup>D1/+</sup> line was 1070 crossed out with Control<sup>A</sup>. Unpaired two-tailed t-test, error bars represent SEM. D) 1-1071 week old F-actin stained Drosophila hearts with or without heterozygous loss-of-function  $CHCHD^{D1/+}$  in the background, 20µm scale. 1072

1073 Supp. Figure 4: A) End-Diastolic diameter and B) End-systolic diameter measured from 1074 1-week old female flies with KD of individual MICOS subunits and Sam50 using a Hand<sup>4.2</sup>-1075 Gal4 driver. C) F-actin cardiac sarcomere staining in 1-week old female flies with Hand<sup>4.2</sup>-Gal4 KD. D) All MICOS subunits and Sam50 were knocked down with Hand<sup>4.2</sup>-Gal4. tdtK 1076 (filled squares) or using the sensitizer line Hand<sup>4.2</sup>-Gal4, tdtK; CHCHD<sup>D1/+</sup> (empty 1077 1078 squares) at 25°C. Two-way ANOVA with Tukey's multiple comparisons test, only 1079 statistical comparisons between same RNAi lines are shown; error bars represent SEM, 1080 20µm scale.

1081 Supp. Figure 5: A, B) Cardiac cell proliferation assay following MICOS complex subunit 1082 KD, individually and in combination using EdU (proliferation marker, green) and ACTN1 1083 (cardiac-specific, red) in ventricle-like cardiomyocytes (VCMs). A) VCMs showing reduced proliferation with siCHCHD6. B) Quantification of proliferation between siRNA 1084 1085 mediated KD of individual MICOS subunits and MICOS subunit combination KDs in VCMs 1086 (siTP53 is a positive control). One-way ANOVA with Dunnett's multiple comparisons test, 1087 \* $p \le 0.05$ , \*\*\* $p \le 0.001$ , \*\*\*\* $p \le 0.0001$ ; error bars represent standard deviation. One-way ANOVA with Dunnett's multiple comparisons test,  $p \le 0.05$ ,  $p \le 0.001$ ,  $p \le 0.001$ ; 1088 1089 error bars represent standard deviation.

Supplementary Table 3: CHCHD3 and CHCHD6 MICOS variants in HLHS probands.
 Rare, predicted-damaging variants in CHCHD3 and CHCHD6 were identified in 6 of 183
 HLHS probands in the Mayo Clinic cohort and the Pediatric Cardiac Genomics
 Consortium (PCGC). Transcript and relevant protein variants are listed. Corresponding
 *Drosophila* orthologs and orthology scores (DIOPT) are additionally listed (Hu *et al.*,
 2011). Note that probands 87H and 363H both harbor *APOO* and *SAM50* variants.

1096 Figure 6: HLHS CHCHD3 and CHCHD6 family-based gene interaction screen reveals three hits. A) A Hand<sup>4.2</sup>-Gal4, tdtK; CHCHD3/6<sup>RNAiC1</sup> sensitizer line show 1097 1098 reduced fractional shortening at 25°C, which is no longer significant at 21°C. Unpaired 1099 two-tailed t-test, \*\*\*\*p≤ 0.0001; error bars represent SEM. B) Genetic interaction of 1100 CHCHD3/6 and prioritized HLHS candidates. Two-way ANOVA with Tukey's multiple 1101 comparisons test, only statistical comparisons between the same RNAi lines are shown; 1102 \*\*\* $p \le 0.001$ , \*\*\*\* $p \le 0.0001$ ; error bars represent SEM. C) Functional overview of human 1103 and Drosophila orthologs. KD of Ckd12 with CHCHD3/6 KD led to increased lethality of 1104 eclosed flies by 1 week-of-age.

#### 1105 Supplementary Table 4: Candidate genes from HLHS probands harboring CHCHD3

1106 or *CHCHD6* variants. The majority of HLHS candidate genes has a *Drosophila* ortholog

1107 (genes without ortholog highlighted in green).


# **F.** 1

A 11H family pedigree


Β

Hand <sup>4.2</sup> -Gal4	Heart tube Pericardial cells

Human Gene	Fly Gene	DIOPT	Fly phenotype when knocked down ( <i>Hand</i> <sup>4.2</sup> )
RHBDL2	rho-4	6	Ø
CAP1	capt	14	Constricted, ✔ Cardiac output
SZT2	No fly ortholog		
RNF149	gol	7	Ø
CHCHD6	CHCHD3/6	6	$\mathbf{\Psi}\mathbf{\Psi}$ Contractility
MTRR	CG14882	8	Ø
MBTPS1	S1P	14	Ø
DGKE	Dgkepsilon	13	Arrhythmic, Dilated
C17orf67	No fly ortholog		




#### S. F. ′




# **T.** 1

<u> </u>		-									
Gene symbol	Chr	BP Position (HG38)	Transcript variant	Gene Region	Protein variant	rsID	RegulomeDB Rank for Regulatory Variants	CADD Score for Missense Variants (Percentile)	Genotyp	Genotype in brother	gnomA D MAF (%)
RHBDL2	1	38941780	c224C>T	5'UTR		rs570057342	4		Hom	Het	0.05
CAP1	1	40039733	c1061C>T; c 1079C>T	Promoter		rs1033279388	4		Hom	Het	not reported
SZT2	1	43427349	c.3331G>T	Exonic	p.D1111Y	rs887336448		27 (85)	Hom	Het	not reported
RNF149	2	101308657	c69C>G	5'UTR		rs78958738	4		Het	Hom	0.65
CHCHD6	3	126704425	c.87+26C>A	Intronic		rs768047544	2b		Het	Hom	0.00
MTRR	5	7889130	c.1263C>G; c.1182C>G	Exonic	p.D394E; p.D421E	rs149678769		8 (15)	Het	Hom	0.05
MBTPS1	16	84056017	c.2950G>A	Exonic	p.D984N	rs146299475		24 (65)	WT	WT	0.66
DGKE	17	56833747	c532A>C	Promoter		rs911884815	4		WT	Het	0.00
C17orf67	17	56833747	c1131T>G	5'UTR		rs911884815	4		WT	Het	0.00









#### S. F. 2 A

Human	Fly	Phenotype (Hand <sup>4.2</sup> ; tdtK>)			
O a filling	4	lethal			
Cofilin	tsr	lethal			
Profilin	chic	Ø			
FIOIIIII	CHIC	lethal			
Arp2/3	Arp				
		Ø			
Qalaslin					
Gelsolin	gel	Ø			
		Ø			
Transgelin	Chd64				
WASP	WASp				
		<b>↓</b> FS ( <b>↓</b> DD)			
	\/lin_4	Ø			
WIP	Verprolin 1	Ø			
		Ø			
Formins	DAAM	Ø			
Tropomyosin	Tm1				
nopeniyooni		Ø			








### S. T. 2

Mitochondrial functional group	Gene	RNAi line	Functional phenotype	Structural (F- actin) phenotyp
		RNAiA		Yes
	ATPsynB (C.V)	RNAiB		Yes
	ATPsynβ (C.V)	RNAiA		Yes
	ATPsynγ (C.V)	RNAiA		Yes
	ATPsynGL (C.V)	RNAiA	Ø	Ø
	blw (C.V)	RNAiA		Yes
	ATPsynC (C.V)	RNAiB		Yes
ETC		RNAiB	Ø	Ø
	mtND2 (C.I)	RNAiC	<b>↓</b> FS ( <b>↓</b> DD)	Ø
	ND-75 (C.I)	RNAiB		Ø
	SdhC (C.II)	RNAiC	<b>↓</b> FS ( <b>↓</b> DD)	Ø
		RNAiA		<b>O</b>
	Cyt-c1 (C.III)	RNAiB		<b>O</b>
		RNAiB	Ø	<b>O</b>
	mtCo1 (C.IV)	RNAiC	<b>↓</b> FS ( <b>↓</b> DD)	<b>O</b>
	Drp1	RNAiA	Ø	<b>O</b>
	Marf	RNAiA		<b>O</b>
<b>Fission fusion</b>	IVIALI	RNAiB		<b>O</b>
	One1	RNAiB		<b>O</b>
	Opa1	RNAiC	<b>↓</b> FS ( <b>↓</b> DD)	<b>O</b>
	Dork	RNAiA	Ø	<b>O</b>
Cellular recycling	Park	RNAiB	Ø	<b>O</b>
	Diap	RNAiC	Ø	Ø
Mitophonduial transporter	Dimo	RNAiA	$\otimes$	Ø
Mitochondrial transporter	Rim2	RNAiB	$\otimes$	Ø
Mitochondria translation initiation factor	mIF2	RNAiC	<b>↓</b> FS ( <b>↓</b> DD)	0
Heat shock protein chaperones 60	Hsp60A	RNAiC	0	0
Mitochondrial biogenesis	Srl	RNAiB	<b>O</b>	Ø
Mitochondrial biogenesis	511	RNAiC	<b>O</b>	Ø
Maintains cardiolipin	Taz	RNAiB	<b>O</b>	Ø


# S. F. 3









S. F. 4




# S. F. 5






#### S. T. 3

Gene Symbol	Proband	Mode of Inheritance	Transcript variant	Protein variant	rsID	RegulomeD B Rank for regulatory	CADD score for missense variants	gnomAD MAF (%)	Fly homolog	DIOPT score
						variants	(percentile )			
	11H	homozygous recessive	c.87+26C>A		rs76804754 4	2b		0.001		
CHCHD6	158H	maternal	c.567- 12104G>A		rs97050528 7	2a		0.023		6
	228H	unknown	c.622T>C	p.Y208H	rs14502075 4		28 (90)	0.124		
	287H	maternal	c.524+1502C> G		N/A	2a		Not reported	CHCHD3/ 6	
	199H	maternal	c.524+1429A> G;		rs91114992 7	4		Not reported	0	
CHCHD3	179H	de novo	c.370- 1242A>T; *c.371A>T	*p.D124	N/A		18 (35)	Not reported		11
	PCGC	transmitted	c.250C>T	p.R84X	rs88939398 8			0.0004		



С				Lethality			
	Human gene	Fly gene	DIOPT	Function	RNAi line	Hand <sup>4.2</sup> , tdtK>	<i>Hand<sup>4.2</sup></i> , tdtK; CHCHD3/6 <sup>RNAiC1</sup> >
	RNF149	Goliath	7	Ubiquitination, mesoderm formation	Gol <sup>RNAiA1</sup>	0%	0%
	KINF 149	Gonain	7		Gol <sup>RNAiA2</sup>	0%	0%
	CdK12	Cdk12	11	Transcription,	Cdk12 <sup>RNAiA1</sup>	47%	77%
	CURTZ	Cakiz	11	RNA splicing	Cdk12 <sup>RNAiA2</sup>	50%	88%
	SPTBN1	β-Spectrin	15	Crosslinks with actin, scaffolding	β-Spec <sup>RNAiA1</sup>	0%	0%

#### Hand<sup>4.2</sup>, tdtK; CHCHD<sup>RNAiC1</sup>>



S. T. 4

CHCHD3 (PCGC)	CHCHD3 (199H)	CHCHD3 (179H)	CHCHD6 (11H)	CHCHD6 (158H)	CHCHD6 (228H)
ASIC5	BRPF3	LARGE	TTN	SPTBN1	LRP5
CCNB2	MCF2	TTN	RHBDL2	HNRNPAB	LZTS2
FMNL1	CDH12	POLD1	CAP1	KLHL4	RBM33
KMT2D	CMYA5	PLCL2	RNF149	RSBN1	SPEG
ZW10	NDUFS7	FARP1	MTRR	BUB1	MYH6
COG4	ZNF652	PTPRQ	MBTPS1	ANAPC1	FNDC4
COL6A6	PAN2	MAPK8IP3	DGKE	AADACL2	
NT5C1B-RDH14		HNRNPU	MSI2	TRIO	
		SYNE1	PABPC4	DISP2	
		EP400	RNF220	ABR	
		NAA25	ZBTB20	TECR	
		MYH6	MAML3	HUWE1	
		KALRN	CDH13	GPM6B	
			ST3GAL3	AUTS2	
			CNOT11	NOTCH3	
			ITGA9	CACNA1C	
			TAGLN3	PDCD10	
			ADCY5	BCL2L11	
			ITGB5	CCDC3	
			NPRL2		
			NPRL3		
			EIF2S3		
			CDK12		
			HEG1		
			EBP		
			SZT2		
			C17orf67		
			PITPNB		
			PAN2		

No fly homolog Bold: Interaction identified